<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Propranolol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Propranolol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Propranolol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11004" href="/d/html/11004.html" rel="external">see "Propranolol: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12744" href="/d/html/12744.html" rel="external">see "Propranolol: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F214907"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Hemangeol;</li>
<li>Inderal LA;</li>
<li>Inderal XL;</li>
<li>InnoPran XL</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868062"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Propranolol;</li>
<li>Hemangiol;</li>
<li>Inderal LA [DSC];</li>
<li>LUPIN-Propranolol LA;</li>
<li>TEVA-Propranolol</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F214939"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antianginal Agent;</li>
<li>
                        Antiarrhythmic Agent, Class II;</li>
<li>
                        Antihypertensive;</li>
<li>
                        Beta-Blocker, Nonselective</li></ul></div>
<div class="block doa drugH1Div" id="F214911"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing recommendations are expressed as the total daily dose unless stated otherwise. The total daily oral dose is given in 1 to 4 divided doses per day, depending on the type of preparation. Oral IR (usually dosed 2 to 4 times daily), ER (usually dosed once daily), and IV injection formulations are available. If tolerability is a concern, immediate release may be preferred initially; after establishing appropriate maintenance dose, may convert to once-daily extended release using same total daily dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34cc2c7c-f48e-43c2-99c1-d056a74ca772">Akathisia, antipsychotic-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Akathisia, antipsychotic-induced (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 10 mg twice daily; if needed, adjust dose based on response and tolerability (eg, at intervals of ≥1 week) up to 120 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2877708','lexi-content-ref-32867516','lexi-content-ref-2577308','lexi-content-ref-Stroup.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2877708','lexi-content-ref-32867516','lexi-content-ref-2577308','lexi-content-ref-Stroup.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13bd6bb4-812a-4adb-9d1b-a07b36a7a601">Angina, chronic stable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina, chronic stable (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For vasospastic angina, beta-blockers are not recommended; other agents (eg, calcium channel blockers or nitrates) are preferred. For nonvasospastic angina, titrate dose to a resting heart rate of 55 to 70 beats per minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211','lexi-content-ref-Kannam.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211','lexi-content-ref-Kannam.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 80 mg/day in 1 to 4 divided doses based on chosen formulation (may choose an IR or ER formulation); increase dose as tolerated to desired effect; usual dosage range: 80 to 320 mg/day in 1 to 4 divided doses based on chosen formulation. Also see “Note: Dosage Forms” above.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9998ecf1-cec8-46bc-96a5-5289902ef8d0">Atrial fibrillation/flutter</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation/flutter:</b></p>
<p style="text-indent:0em;margin-left:2em;">
<b>Note: </b>For unstable patients, electrical cardioversion is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24685669','lexi-content-ref-33081529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24685669','lexi-content-ref-33081529'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Acute ventricular rate control (alternative agent): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 1 mg over 1 minute; repeat as needed every 2 minutes up to a maximum of 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24685669','lexi-content-ref-Kaplan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24685669','lexi-content-ref-Kaplan.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Maintenance of ventricular rate control:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: <b>Oral: </b>Initial: 10 mg 3 to 4 times daily; increase dose gradually as tolerated to achieve ventricular rate control up to 40 mg 3 to 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24685669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24685669'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: <b>Oral:</b> 60 mg once daily; increase dose gradually as tolerated to achieve ventricular rate control up to 160 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kaplan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kaplan.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="79514b59-1174-4fcb-ac68-983885af5284">Burns, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Burns, moderate to severe (hypermetabolism modulation) (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 10 to 20 mg 3 to 4 times daily; titrate as tolerated to a heart rate decrease of 15% to 20% from baseline. Generally, start within the first ~7 days following injury, after the patient is hemodynamically stable; usual total daily dosage range: 0.5 to 2 mg/kg/day in 3 to 6 equally divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31931932','lexi-content-ref-34895792','lexi-content-ref-19826272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31931932','lexi-content-ref-34895792','lexi-content-ref-19826272'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="353cf100-c3b0-4138-b9a4-c27a19d23ac6">Essential tremor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Essential tremor:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as monotherapy or in combination with primidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15972843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15972843'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 60 to 80 mg/day in 1 to 4 divided doses based on chosen formulation (may choose an IR or ER formulation); increase dose as needed based on response and tolerability; usual dosage range: 60 to 360 mg/day in 1 to 4 divided doses based on chosen formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15972843','lexi-content-ref-22013182','lexi-content-ref-21256454','lexi-content-ref-31046186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15972843','lexi-content-ref-22013182','lexi-content-ref-21256454','lexi-content-ref-31046186'])">Ref</a></span>). Also see "Dosing" above.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Not recommended in the absence of specific comorbidities (eg, ischemic heart disease, essential tremor, migraine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 80 mg/day in 1 to 4 divided doses based on chosen formulation (may choose an IR or ER formulation); titrate at ≥1-week intervals as needed based on patient response; usual dosage range: 80 to 160 mg/day in 1 to 4 divided doses based on chosen formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>). Also see "Note: Dosage Forms" above.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An adequate trial for assessment of effect is considered to be at least 2 to 3 months at a therapeutic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 40 to 80 mg/day in 1 to 4 divided doses based on chosen formulation (may choose an IR or ER formulation); increase dose gradually based on response and tolerability to usual effective dosage range of 40 to 240 mg/day in 1 to 4 divided doses based on chosen formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15106196','lexi-content-ref-20159899','lexi-content-ref-Schwedt.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15106196','lexi-content-ref-20159899','lexi-content-ref-Schwedt.2022'])">Ref</a></span>). Also see "Note: Dosage Forms" above.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="51b05bef-6600-468e-9957-c474e5eda739">Myocardial infarction, early treatment and secondary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocardial infarction, early treatment and secondary prevention (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> An <b>oral</b> beta-blocker is recommended within the first 24 hours for most patients. Patients who did not receive a beta-blocker within 24 hours of myocardial infarction should be reevaluated for secondary prevention at a later date (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 60 to 120 mg/day in 2 to 3 divided doses; titrate dose based on heart rate and blood pressure as tolerated up to 240 mg/day. The optimal duration of therapy is unknown; treat for a minimum of 3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-7038157','lexi-content-ref-6799077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-7038157','lexi-content-ref-6799077'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f4527aa-2bf1-4e41-8e28-b49e2893adc9">Performance anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Performance anxiety disorder (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> 10 or 20 mg administered 30 to 60 minutes prior to anxiety-provoking situation; if initial dose is not sufficiently effective, may increase by 10 to 20 mg prior to next anxiety-provoking situation up to a maximum of 60 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6871565','lexi-content-ref-Stein.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6871565','lexi-content-ref-Stein.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="678d411f-b3ca-40d9-8568-e75b9195bd73">Pheochromocytoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pheochromocytoma (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> An alpha-1 blocker <b>must</b> be started several days before propranolol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24893135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24893135'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 10 mg every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Young.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Young.1'])">Ref</a></span>) or 20 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24893135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24893135'])">Ref</a></span>); begin 3 to 4 days after initiation of an alpha-1 blocker and adjust to goal heart rate up to 120 mg/day in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24893135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24893135'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b2d2bcf-2892-4c38-946f-df5b5abfc5de">Postural orthostatic tachycardia syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postural orthostatic tachycardia syndrome (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release:<b> Oral: </b>Initial: 10 mg twice daily; may increase based on response and tolerability to a maximum of 20 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23616163','lexi-content-ref-29500811','lexi-content-ref-19687359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23616163','lexi-content-ref-29500811','lexi-content-ref-19687359'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f882e79-d62c-4b63-bf32-63cd49609f40">Supraventricular tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Supraventricular tachycardia (eg, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, focal atrial tachycardia):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Acute treatment (alternative agent) (off-label dose):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: 1 mg over 1 minute; repeat as needed every 2 minutes up to 3 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Initiate cautiously in patients with heart failure. Avoid in patients with decompensated heart failure; electrical cardioversion preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Maintenance therapy (off-label use): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: <b>Oral:</b> Initial: 30 to 60 mg/day in 2 or 3 divided doses titrated to effect; maximum recommended dose: 160 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1475225-321a-4979-8339-62b5dcdf93d0">Thyroid storm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid storm (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For control of adrenergic symptoms until thyroid storm has resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>). Avoid use in patients with decompensated low-output heart failure (systolic dysfunction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-9833593','lexi-content-ref-32167428','lexi-content-ref-17127140','lexi-content-ref-1603141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-9833593','lexi-content-ref-32167428','lexi-content-ref-17127140','lexi-content-ref-1603141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 60 to 80 mg every 4 to 6 hours adjusted based on heart rate and blood pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-Ross.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-Ross.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 0.5 to 1 mg administered over 10 minutes while under continuous cardiac monitoring; a repeat dose of 1 to 3 mg over 10 to 15 minutes may be given every few hours as needed until oral therapy can be initiated and takes effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Braverman.2013','lexi-content-ref-Ross.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Braverman.2013','lexi-content-ref-Ross.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63559ecb-74fc-4e35-b0bd-95b480b146f7">Thyrotoxicosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyrotoxicosis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For control of cardiovascular effects until euthyroidism established.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 30 to 160 mg/day in 1 to 4 divided doses based on chosen formulation (may choose an IR or ER formulation) adjusted for heart rate and blood pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>). Also see “Note: Dosage Forms” above.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a528bb6b-c2fc-49e1-ad4e-2ada00b35206">Tremor, lithium-induced, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tremor, lithium-induced, moderate to severe (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 10 mg 3 to 4 times daily; if needed, titrate dose based on response and tolerability up to 80 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7615481','lexi-content-ref-4127340','lexi-content-ref-1260604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7615481','lexi-content-ref-4127340','lexi-content-ref-1260604'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18195199-af59-41c2-a88b-528ad1fbde0f">Variceal hemorrhage prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Variceal hemorrhage prophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 10 to 20 mg twice daily; titrate according to resting heart rate (target 55 to 60 beats per minute), while maintaining blood pressure (eg, systolic blood pressure ≥90 mm Hg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27786365','lexi-content-ref-12447861','lexi-content-ref-Sanyal.2','lexi-content-ref-Sanyal.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27786365','lexi-content-ref-12447861','lexi-content-ref-Sanyal.2','lexi-content-ref-Sanyal.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maximal daily dose:</p>
<p style="text-indent:-2em;margin-left:8em;">No ascites: 320 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27786365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27786365'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Ascites: 160 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27786365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27786365'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f42c553-e8c4-4b54-98fb-e270b999dc6b">Ventricular arrhythmias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular arrhythmias: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ventricular tachycardia, hemodynamically stable:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Acute ventricular tachycardia (incessant ventricular tachycardia or electrical storm) (adjunctive agent)</i></b>:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Beta-blockers are generally administered in addition to an IV antiarrhythmic drug (eg, amiodarone). Propranolol may be preferred over other beta-blockers in this setting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29699616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29699616'])">Ref</a></span>). A beta-blocker may also be used to reduce shocks in patients with an implantable cardioverter defibrillator (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 1 to 3 mg every 5 minutes up to a total of 5 mg in combination with an IV antiarrhythmic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release: <b>Oral:</b> 40 mg every 6 hours in combination with an IV antiarrhythmic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29699616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29699616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Prevention of ventricular tachycardia:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release: <b>Oral:</b> Initial: 10 to 40 mg every 6 hours; adjust dose as needed based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-29699616','lexi-content-ref-10942741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-29699616','lexi-content-ref-10942741'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nonsustained ventricular tachycardia or ventricular premature beats, symptomatic:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: <b>Oral:</b> Initial: 10 to 40 mg every 6 hours; adjust dose as needed based on patient response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>). Some experts recommend initiating 10 mg every 8 to 12 hours; then titrate based on response and tolerability to the lowest effective dose that alleviates symptoms; maximum dose: 320 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manolis.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manolis.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: <b>Oral:</b> Initial: 80 mg once daily; then titrate based on response and tolerability to the lowest effective dose that alleviates symptoms; maximum dose: 320 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manolis.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manolis.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991243"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4426144','lexi-content-ref-7470370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4426144','lexi-content-ref-7470370'])">Ref</a></span>); use with caution, particularly in patients with more advanced kidney impairment, as decreased hepatic extraction has been reported and patients may be more prone to adverse effects when initiating therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4426144']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4426144'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4426144']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4426144'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988493"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, hepatic impairment increases systemic exposure to propranolol. Use with caution.</p></div>
<div class="block doe drugH1Div" id="F214912"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Use caution; initiate at lower end of the dosing range.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Refer to adult dosing; consider lower initial doses and titrate to response.</p></div>
<div class="block dop drugH1Div" id="F214926"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12744" href="/d/html/12744.html" rel="external">see "Propranolol: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Oral liquid solutions are available in multiple concentrations (generic oral solution: 4 mg/mL [20 mg/5 mL] and 8 mg/mL [40 mg/5 mL]; Hemangeol: 4.28 mg/mL); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as "mg."</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosage should be individualized based on patient response.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7fc4235-c695-4f6f-8b85-6a2ed65e8502">Cyclic vomiting syndrome, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome, prophylaxis: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Prophylaxis is recommended for patients experiencing frequent symptoms (eg, monthly) or severe symptoms (eg, requiring hospitalization, lasting &gt;2 days, resulting in significant school/work absences) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24898244','lexi-content-ref-30076469','lexi-content-ref-18728540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24898244','lexi-content-ref-30076469','lexi-content-ref-18728540'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: Immediate-release formulations: 0.25 to 1 mg/kg/day in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30076469','lexi-content-ref-18728540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30076469','lexi-content-ref-18728540'])">Ref</a></span>). Maximum daily dose: 80 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sunku.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sunku.2009'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="353cf100-c3b0-4138-b9a4-c27a19d23ac6">Essential tremor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Essential tremor:</b> Limited data available: Children and Adolescents: Oral: Immediate-release formulations: Initial: 0.5 to 1 mg/kg/day in 3 divided doses; maximum daily dose: 4 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19725596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19725596'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5427f27-c2a4-4f84-881f-8318f5daede4">Hemangioma, infantile; proliferating</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemangioma, infantile; proliferating:</b></p>
<p style="text-indent:-2em;margin-left:4em;">In-person evaluation:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hemangeol</i>: Infants ≥5 weeks and ≥2 kg: <b>Note:</b> Therapy should be initiated at age 5 weeks to 5 months: Oral: Initial dose: 0.6 mg/kg/<b>dose</b> twice daily for 1 week, then increase dose to 1.1 mg/kg/<b>dose</b> twice daily for 1 week, and then increase to a maintenance dose of 1.7 mg/kg/<b>dose</b> twice daily for 6 months; doses should be separated by at least 9 hours; readjust dose for patient growth. May repeat course if hemangiomas recur.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate-release formulations</i>: Limited data available: Infants and Children &lt;5 years: Oral: Initial: 1 mg/kg/day in 2 or 3 divided doses, increase by 1 mg/kg/day at weekly intervals to maintenance dose; usual daily maintenance dose: 1 to 3 mg/kg/day in 2 or 3 divided doses; optimal duration not defined, duration ranged from 3 to 12 months; discontinuation of therapy may be gradually tapered over 1 to 3 weeks to prevent rebound sinus tachycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26416931','lexi-content-ref-36243426','lexi-content-ref-21788220','lexi-content-ref-32662682','lexi-content-ref-25693013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26416931','lexi-content-ref-36243426','lexi-content-ref-21788220','lexi-content-ref-32662682','lexi-content-ref-25693013'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Telemedicine evaluation:<i> Hemangeol, immediate-release formulations:</i> Limited data available: Infants &gt;5 weeks: Oral: Initial: 0.5 mg/kg/day in 2 divided doses; may increase by 0.5 mg/kg/day every 3 to 4 days as tolerated to a target dose of 2 to 3 mg/kg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32298480','lexi-content-ref-36243426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32298480','lexi-content-ref-36243426'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic (alternate agent):</b>
<b>Note: </b>Beta-blockers are not recommended as initial antihypertensive agents in children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents ≤17 years: Immediate-release formulations: Oral: Initial: 1 to 2 mg/kg/day divided in 2 to 3 doses/day; titrate dose to effect; maximum daily dose: 4 mg/kg/<b>day</b> up to 640 mg/<b>day</b>; sustained-release formulation may be dosed once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286277','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286277','lexi-content-ref-NIH.1'])">Ref</a></span>). Others have suggested a higher maximum daily dose of 16 mg/kg/<b>day</b> up to 640 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17137886','lexi-content-ref-20937444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17137886','lexi-content-ref-20937444'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a88a9dbf-8161-4267-8b85-a53eda1346a9">Migraine, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prophylaxis:</b> Limited data available; efficacy results variable; optimal dose not established:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Immediate-release formulations:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: Children ≥3 years and Adolescents: Oral: Reported range: 0.5 to 3 mg/kg/day in 2 to 3 divided doses; some trials initiated therapy at the low end of the range and titrated upward to response; doses as low as 0.5 to 1 mg/kg/day may be effective; doses up to 4 mg/kg/day have been recommended; maximum daily dose: 120 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15623677','lexi-content-ref-16120482','lexi-content-ref-23303551','lexi-content-ref-22633628','lexi-content-ref-24400971','lexi-content-ref-3822681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15623677','lexi-content-ref-16120482','lexi-content-ref-23303551','lexi-content-ref-22633628','lexi-content-ref-24400971','lexi-content-ref-3822681'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dose: Children ≥7 years and Adolescents: Oral: Initial: 10 mg daily; increase at weekly intervals in 10 mg increments; reported dose range: 10 to 40 mg three times daily; maximum dose: 120 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15623677','lexi-content-ref-Hershey.1','lexi-content-ref-4839065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15623677','lexi-content-ref-Hershey.1','lexi-content-ref-4839065'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d4f91f8f-15fb-4792-812d-c8135ea66fef">Tachyarrhythmias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tachyarrhythmias:</b> Limited data available: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Immediate-release formulations: Initial: 0.5 to 1 mg/kg/day in divided doses every 6 to 8 hours; titrate dosage upward every 3 to 5 days; usual daily dose: 2 to 4 mg/kg/day; higher doses may be needed; maximum daily dose: 16 mg/kg/<b>day</b> or 60 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dalal.1','lexi-content-ref-Park.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dalal.1','lexi-content-ref-Park.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 0.01 to 0.15 mg/kg/<b>dose</b> slow IV over 10 minutes; may repeat every 6 to 8 hours as needed; maximum dose is age-dependent: Infants: 1 mg/<b>dose</b>; children and adolescents: 3 mg/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dalal.1','lexi-content-ref-Park.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dalal.1','lexi-content-ref-Park.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d0d68bbf-84b3-496a-bb74-6d9721d51938">Tetralogy spells</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tetralogy spells:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Immediate-release formulations: Infants and Children: 0.5 to 1 mg/kg/<b>dose</b> every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bernstein.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bernstein.1'])">Ref</a></span>). Others have used the following: Initial: 0.25 mg/kg/<b>dose</b> every 6 hours (1 mg/kg/day); if ineffective within first week of therapy, may increase by 1 mg/kg/day every 24 hours to maximum of 5 mg/kg/day; if patient becomes refractory may increase slowly to a maximum of 10 to 15 mg/kg/day but must carefully monitor heart rate, heart size, and cardiac contractility; average dose: 2.3 mg/kg/day; range: 0.8 to 5 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6164284']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6164284'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infants and Children: 0.15 to 0.25 mg/kg/<b>dose</b> infused over 10 minutes; maximum initial dose: 1 mg; may repeat dose once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435'])">Ref</a></span>); alternatively, initiate lower doses of 0.015 to 0.02 mg/kg/<b>dose</b> and titrate to effect, up to 0.1 to 0.2 mg/kg/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Anderson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Anderson.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63559ecb-74fc-4e35-b0bd-95b480b146f7">Thyrotoxicosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyrotoxicosis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Oral: Immediate-release formulations: 0.5 to 2 mg/kg/day divided every 6 to 12 hours; maximum dose: 40 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Kliegman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Kliegman.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: Immediate-release formulations: 10 to 40 mg every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-27521067'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1475225-321a-4979-8339-62b5dcdf93d0">Thyroid storm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid storm</b>: Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Oral: Immediate-release formulations: 1 to 4 mg/kg/day in divided doses, titrate based on blood pressure and heart rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cameron.1','lexi-content-ref-Fuhrman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cameron.1','lexi-content-ref-Fuhrman.1'])">Ref</a></span>); usual frequency in adolescents and adults is every 4 to 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-Smith.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-Smith.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Immediate-release formulations: 20 to 40 mg every 4 to 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Smith.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Smith.1'])">Ref</a></span>); titrate based on blood pressure and heart rate; doses as high as 60 to 80 mg every 4 hours have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 0.5 to 1 mg slow IV push over 10 minutes, then may repeat dose with 1 to 3 mg slow IV push over 10 to 15 minutes every several hours with continuous cardiac monitoring until heart rate controlled or oral therapy initiated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Braverman.2013','lexi-content-ref-Smith.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Braverman.2013','lexi-content-ref-Smith.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159510"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<i>Immediate-release formulations</i>: Not dialyzable. There are no dosage adjustments provided in the manufacturer's labeling; however, renal impairment increases systemic exposure to propranolol. Use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51159511"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<i>Immediate-release formulations</i>: There are no dosage adjustments provided in the manufacturer's labeling; however, propranolol is extensively metabolized by the liver; hepatic impairment increases systemic exposure to propranolol. Use with caution.</p></div>
<div class="block arsc drugH1Div" id="F55709477"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bradyarrhythmias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may cause <b>first-degree atrioventricular </b>(AV)<b> block</b>, <b>second-degree atrioventricular block</b>, or<b> complete atrioventricular block</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162','lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162','lexi-content-ref-15234417'])">Ref</a></span>). At maintenance dosing, second- or third-degree AV block are less likely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2450898'])">Ref</a></span>). Beta-blocking agents with intrinsic sympathomimetic activity (eg, pindolol) may cause fewer AV conduction abnormalities than those without intrinsic sympathomimetic activity (eg, propranolol) due to their partial agonist effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2895072','lexi-content-ref-1977302','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2895072','lexi-content-ref-1977302','lexi-content-ref-2450898'])">Ref</a></span>). In most cases (up to 72%), AV block associated with a beta-blocker will resolve upon discontinuation; however, there are reported cases of recurrent AV block and nearly 50% of patients with more severe AV block may require a permanent pacemaker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22530749','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22530749','lexi-content-ref-32929996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Blockade of cardiac beta-1 adrenergic receptors results in slowed conduction and prolongation in the refractory period of the AV node. Slowing of AV conduction can lead to AV block (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162','lexi-content-ref-2450898','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162','lexi-content-ref-2450898','lexi-content-ref-32929996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; one study included patients who were on beta-blocker for more than one month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>); however, other studies noted prolongation of the PR interval or AV nodal refractory period occurring anywhere from one dose to several days following treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897302','lexi-content-ref-2450898','lexi-content-ref-947574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897302','lexi-content-ref-2450898','lexi-content-ref-947574'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired AV node conduction or sinus node dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acute myocardial infarction (MI) (especially inferior and posterior MI) or heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29766868']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29766868'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other agents that impair AV nodal conduction (eg, nondihydropyridine calcium channel blockers, digoxin, ivabradine, select antiarrhythmic agents) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bronchospasm</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonselective beta-blockers (eg, propranolol) have a higher risk of <b>bronchospasm</b> compared to cardioselective beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27390282','lexi-content-ref-6344309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27390282','lexi-content-ref-6344309'])">Ref</a></span>) and may lead to drug discontinuation in patients with chronic obstructive pulmonary disease (COPD) or asthma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12490274','lexi-content-ref-6344309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12490274','lexi-content-ref-6344309'])">Ref</a></span>). Concurrent use of inhaled bronchodilators and/or corticosteroids are protective against beta-blocker-induced bronchospasm in patients with COPD or asthma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12490274','lexi-content-ref-27390282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12490274','lexi-content-ref-27390282'])">Ref</a></span>). Bronchospasm is reversible upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2439802']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2439802'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to pharmacologic action. Beta-blocking agents can lead to airway smooth muscle constriction by antagonism of beta-2 receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15579370','lexi-content-ref-27390282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15579370','lexi-content-ref-27390282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; reports after one dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-526710','lexi-content-ref-6344309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-526710','lexi-content-ref-6344309'])">Ref</a></span>). In another study with carvedilol-induced bronchospasm, the onset appeared to be slightly longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12490274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12490274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with asthma who possess 1 or 2 copies of arginine-16 beta-2 receptor polymorphism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27390282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27390282'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acute use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24202435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24202435'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may cause reversible CNS effects such as <b>fatigue</b>,<b> insomnia</b>, <b>vivid dreams</b>,<b> memory impairment</b>, and<b> sexual disorder</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714','lexi-content-ref-12117400','lexi-content-ref-15288162','lexi-content-ref-1969642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714','lexi-content-ref-12117400','lexi-content-ref-15288162','lexi-content-ref-1969642'])">Ref</a></span>). Sexual disorders may occur; however, patients who require beta-blocker therapy have risk factors for erectile dysfunction (eg, coronary artery disease, heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29746858','lexi-content-ref-12117400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29746858','lexi-content-ref-12117400'])">Ref</a></span>). In addition, there may be a psychosomatic component (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18654082','lexi-content-ref-14585251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18654082','lexi-content-ref-14585251'])">Ref</a></span>). Lipophilic beta-blockers (such as propranolol, which is highly lipophilic) penetrate the blood-brain barrier to a greater extent than hydrophilic beta-blockers, possibly leading to a greater incidence of CNS effects; however, other studies have refuted this theory (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969642','lexi-content-ref-1969714','lexi-content-ref-2865153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969642','lexi-content-ref-1969714','lexi-content-ref-2865153'])">Ref</a></span>). CNS effects generally resolve with dose reduction or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; exact mechanism is not fully understood. Proposed mechanisms include presence of beta receptors in the brain, affinity and in some instances, inhibition of beta-blocking agents towards serotonin (5-HT) receptors in the brain (affecting mood and sleep), and beta-blocker-induced decreases in central sympathetic output (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8956349','lexi-content-ref-2865151','lexi-content-ref-2878741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8956349','lexi-content-ref-2865151','lexi-content-ref-2878741'])">Ref</a></span>). Beta-1 blockade may also impact sleep by blocking sympathetic signaling to the pineal gland, resulting in suppression of nighttime levels of melatonin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23024438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23024438'])">Ref</a></span>). Beta-blockers may cause erectile dysfunction through decreased sympathetic nervous system output and subsequent decreases in luteinizing hormone secretion and testosterone stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24155101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24155101'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; CNS effects often occur within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher starting doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969642'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Potentiation/masking of hypoglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may worsen, prolong, or cause <b>hypoglycemia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749','lexi-content-ref-6376011','lexi-content-ref-2861072','lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749','lexi-content-ref-6376011','lexi-content-ref-2861072','lexi-content-ref-Vue.1'])">Ref</a></span>). Additionally, beta-blockers may mask symptoms of hypoglycemia (tremor, irritability, palpitations), making diaphoresis the only symptom unaffected by beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vue.1'])">Ref</a></span>). It is unclear if non-selective or selective beta blockers are more likely to cause hypoglycemia as data are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749','lexi-content-ref-20067434','lexi-content-ref-85053','lexi-content-ref-6376017','lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749','lexi-content-ref-20067434','lexi-content-ref-85053','lexi-content-ref-6376017','lexi-content-ref-Vue.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Beta-blockers inhibit hepatic gluconeogenesis and glycogenolysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2861072','lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2861072','lexi-content-ref-Vue.1'])">Ref</a></span>). Beta-blockers also reduce activation of the sympathetic nervous system, therefore masking hypoglycemic symptoms that are catecholamine-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vue.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; blood glucose recovery was significantly reduced following one dose or one day of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6376011','lexi-content-ref-85053','lexi-content-ref-6376017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6376011','lexi-content-ref-85053','lexi-content-ref-6376017'])">Ref</a></span>). In another study, episodes of severe hypoglycemia were reported over the course of 4 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28559400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28559400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes mellitus, especially insulin-dependent diabetes and type 2 diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6376011','lexi-content-ref-2861072','lexi-content-ref-6376017','lexi-content-ref-28559400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6376011','lexi-content-ref-2861072','lexi-content-ref-6376017','lexi-content-ref-28559400'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients who are fasting (ie, surgery, not eating regularly, vomiting)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients who are hospitalized and not requiring basal insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blocker therapy should not be withdrawn abruptly, but gradually tapered to avoid acute <b>tachycardia</b>, <b>hypertension</b>, and/or ischemia in patients with underlying cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874','lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874','lexi-content-ref-37093'])">Ref</a></span>). Beta-blocker withdrawal (propranolol <b>withdrawal syndrome</b>), characterized by the development of severe <b>exacerbation of angina pectoris</b>, ventricular arrhythmias, and <b>acute myocardial infarction</b> (MI) has been reported following abrupt withdrawal of beta-blocker therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18617067','lexi-content-ref-436208','lexi-content-ref-1968518','lexi-content-ref-668066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18617067','lexi-content-ref-436208','lexi-content-ref-1968518','lexi-content-ref-668066'])">Ref</a></span>). Some studies have found an increase in propensity-adjusted mortality and cardiovascular events; however, one study did not find changes in infarct size and left ventricular function when beta-blocker was abruptly withdrawn in patients with MI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3009050']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3009050'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-dependent; related to the pharmacologic action. Beta blockade causes upregulation of beta-receptors, enhanced receptor sensitivity, and decreased sympathetic nervous system response. Abrupt withdrawal leads to a transient sympathetic hyper-response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874','lexi-content-ref-436208','lexi-content-ref-6125187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874','lexi-content-ref-436208','lexi-content-ref-6125187'])">Ref</a></span>). Another proposed mechanism involves increased platelet aggregability to epinephrine and thrombin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874','lexi-content-ref-668066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874','lexi-content-ref-668066'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid/varied and transient; increases in heart rate and blood pressure appear 24 hours after abrupt withdrawal, peak after 48 hours, and subside after 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093'])">Ref</a></span>). Anginal symptoms reported to begin 12 to 24 hours after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1244260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1244260'])">Ref</a></span>). Development of adverse reactions also reported to occur 1 to 21 days after withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-668066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-668066'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt withdrawal in chronic users (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Past medical history of coronary artery disease (including chronic stable angina) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897781','lexi-content-ref-2883874','lexi-content-ref-1244260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897781','lexi-content-ref-2883874','lexi-content-ref-1244260'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Past medical history of hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093','lexi-content-ref-1968518','lexi-content-ref-6125187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093','lexi-content-ref-1968518','lexi-content-ref-6125187'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F214869"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Sleep disorder (infants: 16% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchiolitis (infants), bronchitis (infants: 8% to 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cold extremity (infants: 7% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (infants: 4%), constipation (1% to 3%), decreased appetite (infants: 3% to 4%), diarrhea (infants: 5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (infants: 5% to 9%), dizziness (4% to 7%), drowsiness (infants: 5%), fatigue (5% to 7%), irritability (infants: 6%), nightmares (infants: 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Dermatologic: Alopecia, urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (with drug withdrawal) (Fonarow 2008; Psaty 1990), arterial insufficiency, arterial mesenteric thrombosis (Köksal 2005), bradycardia (Clark 1989, Frishman 1988, Léauté-Labrèze 2016), complete atrioventricular block (Zeltser 2004), exacerbation of angina pectoris (with drug withdrawal) (Fonarow 2008, Psaty 1990), first-degree atrioventricular block (López-Sendón 2004), heart failure (Conway 1968, Frishman 1988, Léauté-Labrèze 2016), hypertension (with drug withdrawal) (Lederballe Pederson 1979, Rangno 1982, Shand 1978), hypotension (Ashikaga 2000, de Graaf 2011, Frishman 1988), peripheral arterial disease (exacerbation), Raynaud disease (Frishman 1988, Marshall 1976), second-degree atrioventricular block (including infants and patients with an underlying conduction disorder) (Zeltser 2004), tachycardia (with drug withdrawal) (Lederballe Pederson 1979, Rangno 1982, Shand 1978)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal ulcer, dermatitis (Léauté-Labrèze 2016), erythema multiforme, exfoliative dermatitis, psoriasiform eruption (Kim 2010), purpuric rash, Stevens-Johnson syndrome (Mukul 1989), toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (higher risk in infants) (Holland 2010, Leaute-Labrexe 2016), increased serum potassium (Al-Rwebah 2020, Mandić 2014), weight gain (Boyraz 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, epigastric discomfort (Frishman 1988), increased appetite (Boyraz 2021), ischemic colitis, nausea (Frishman 1988), sore throat, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Peyronie disease (Sommer 2002), sexual disorder (Ko 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Frishman 1988), immune thrombocytopenia, nonthrombocytopenic purpura (Frishman 1988)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (Léauté-Labrèze 2016; Wilkinson 1971), increased serum transaminases (Léauté-Labrèze 2016, Wilkinson 1971)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Jacobs 1981), nonimmune anaphylaxis (Greenberger 1987)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (Léauté-Labrèze 2016), depression (Ko 2002), emotional lability, generalized ache or pain, hallucination (Frishman 1988), insomnia (Frishman 1988), lassitude, memory impairment, tingling of extremities (hands), vivid dream (Frishman 1988), withdrawal syndrome (Shand 1978)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm, lupus-like syndrome (Hughes 1982), myopathy, myotonia, systemic lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Dry eye syndrome, oculomucocutaneous syndrome (involving the skin) (Frishman 1988), visual disturbance (Frishman 1988)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (Kotlyar 2002), dyspnea (Léauté-Labrèze 2016), pharyngitis, respiratory distress (Léauté-Labrèze 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Frishman 1988)</p></div>
<div class="block coi drugH1Div" id="F214885"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to propranolol, beta-blockers, or any component of the formulation; uncompensated heart failure (unless the failure is due to tachyarrhythmias being treated with propranolol); cardiogenic shock; severe sinus bradycardia, sick sinus syndrome, or heart block greater than first-degree (except in patients with a functioning artificial pacemaker); bronchial asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemangeol (additional contraindications): Premature infants with corrected age &lt;5 weeks; infants weighing &lt;2 kg; heart rate &lt;80 bpm; BP &lt;50/30 mm Hg; pheochromocytoma; history of bronchospasm.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Bronchospasm; right ventricular failure secondary to pulmonary hypertension; allergic rhinitis during pollen season; patients prone to hypoglycemia; hypotension (BP parameters not specified in labeling); metabolic acidosis; vasospastic angina (also referred to as Prinzmetal angina or variant angina); severe peripheral arterial circulatory disturbance; untreated pheochromocytoma; hereditary problems of galactose intolerance, glucose-galactose malabsorption, or congenital lactase deficiency (lactose-containing products only).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemangiol (additional contraindications): Infants weighing &lt;2.5 kg; breastfed infants if mother is treated with medicines contraindicated with propranolol; heart rate &lt;100 bpm or BP &lt;65/45 mm Hg (&lt;3 months of age), heart rate &lt;90 bpm or BP &lt;70/50 mm Hg (3 to &lt;6 months of age), heart rate &lt;80 bpm or BP &lt;80/55 mm Hg (6 to 12 months of age).</p></div>
<div class="block war drugH1Div" id="F214866"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse events:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Use with caution in patients with compensated heart failure and monitor for a worsening of the condition (efficacy of propranolol in heart failure has not been demonstrated).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vascular disease and Raynaud disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease and Raynaud disease. Use with caution and monitor for progression of arterial obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with advanced renal impairment during initiation of therapy, as decreased hepatic extraction may result in elevated propranolol concentrations and increase the risk of side effects (Lowenthal 1974).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm. Alterations in thyroid function tests may be observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vasospastic angina: Beta-blockers without alpha-1 adrenergic receptor blocking activity should be avoided in patients with vasospastic angina since unopposed alpha-1 adrenergic receptors mediate coronary vasoconstriction and can worsen anginal symptoms (Mayer 1998).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infants and children: Considerations when treating infantile hemangioma:</p>
<p style="text-indent:-2em;margin-left:6em;">- Cardiovascular concerns: Bradycardia and/or hypotension may occur or be worsened; monitor heart rate and blood pressure after propranolol initiation or increase in dose; discontinue treatment if severe (&lt;80 bpm) or symptomatic bradycardia or hypotension (systolic blood pressure &lt;50 mm Hg) occurs. Infants with large facial infantile hemangioma should be investigated for potential arteriopathy associated with PHACE syndrome prior to propranolol therapy; decreases in blood pressure caused by propranolol may increase risk of stroke in PHACE syndrome patients with cerebrovascular anomalies.</p>
<p style="text-indent:-2em;margin-left:6em;">- Hypoglycemia: May potentiate hypoglycemia and/or mask signs and symptoms. Administer during or after a feeding to minimize the risk for hypoglycemia. Withhold the dose in infants or children who are not feeding regularly or who are vomiting; discontinue therapy and seek immediate treatment if hypoglycemia occurs.</p>
<p style="text-indent:-2em;margin-left:6em;">- Respiratory concerns: May cause bronchospasm. Interrupt therapy in infants or children with lower respiratory tract infection associated with dyspnea or wheezing.</p>
<p style="text-indent:-2em;margin-left:4em;">• Smokers: Cigarette smoking may decrease plasma levels of propranolol by increasing metabolism. Patients should be advised to avoid smoking.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>
<div class="block foc drugH1Div" id="F214877"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Inderal LA: 60 mg, 80 mg, 120 mg, 160 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Inderal XL: 80 mg, 120 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">InnoPran XL: 80 mg, 120 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 60 mg, 80 mg, 120 mg, 160 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemangeol: 4.28 mg/mL (120 mL) [alcohol free, paraben free, sugar free; contains saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/5 mL (5 mL, 500 mL); 40 mg/5 mL (500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</p></div>
<div class="block geq drugH1Div" id="F214862"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F214887"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Inderal LA Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $77.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $89.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $101.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160 mg (per each): $103.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Inderal XL Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $88.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $88.82</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (InnoPran XL Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $88.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $88.82</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Propranolol HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $2.04 - $2.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $2.38 - $2.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $2.98 - $2.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160 mg (per each): $3.88 - $3.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Hemangeol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.28 mg/mL (per mL): $6.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Propranolol HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $9.60 - $12.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Propranolol HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/5 mL (per mL): $0.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/5 mL (per mL): $0.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Propranolol HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.35 - $0.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.51 - $1.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $1.22 - $1.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $0.90 - $0.97</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868063"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Inderal LA: 60 mg [DSC], 80 mg [DSC], 120 mg [DSC], 160 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 60 mg, 80 mg, 120 mg, 160 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4.28 mg/mL (120 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 120 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg, 80 mg</p></div>
<div class="block accres drugH1Div" id="F25573739"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Prescriptions for Hemangeol may be obtained via the Hemangeol Patient Access program.  Visit http://www.hemangeol.com/hcp/hemangeol-direct/ or call 855-618-4950 for ordering information.</p></div>
<div class="block adm drugH1Div" id="F214882"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: IV dose is much smaller than oral dose. When administered acutely for cardiac treatment, monitor ECG and blood pressure. May administer by rapid infusion (IV push) at a rate of 1 mg/minute or by slow infusion over ~30 minutes. Necessary monitoring for surgical patients who are unable to take oral beta-blockers (prolonged ileus) has not been defined. Some institutions require monitoring of baseline and postinfusion heart rate and blood pressure when a patient's response to beta-blockade has not been characterized (ie, the patient's initial dose or following a change in dose). Consult individual institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Tablets (immediate release) should be taken on an empty stomach; capsules (extended release) may be taken with or without food, but should always be taken consistently (with food or on an empty stomach). Do not crush long-acting oral forms.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Capsule, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER capsules should be swallowed whole. Do not crush or chew. IR tablet, oral solution, and injectable formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, selection of IR formulations or alternative therapy should be strongly considered for cardiovascular and other high-risk labeled and off-label indications for propranolol.</p></div>
<div class="block admp drugH1Div" id="F52613722"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release tablets: Take on an empty stomach.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release capsules: Administer consistently either with food or on an empty stomach; do not chew or crush sustained- or extended-release capsules; swallow whole.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: <b>Note:</b> Oral liquid solutions are available in multiple concentrations (generic oral solution: 4 mg/mL [20 mg/5 mL] and 8 mg/mL [40 mg/5 mL]; Hemangeol: 4.28 mg/mL; precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemangeol oral solution: Infants: Administer Hemangeol directly into the child's mouth using the supplied oral dosing syringe; if needed, dose may be diluted with a small quantity of milk or fruit juice and administered in a baby's bottle. Administer during or after a feeding to minimize the risk for hypoglycemia; skip the dose if the patient is not eating or is vomiting. Administer doses at least 9 hours apart. Do not shake bottle before use.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:<b> Note:</b> IV dose is much smaller than oral dose. When administered acutely for cardiac treatment, monitor ECG and blood pressure; consult individual institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates, Infants, Children, and Adolescents: Administer by slow IV injection/infusion over 10 to 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-Braverman.2013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-Braverman.2013'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F214881"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina, chronic stable:</b> To decrease angina frequency and increase exercise tolerance in patients with angina pectoris.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac arrhythmias: </b>Control of supraventricular arrhythmias (eg, atrial fibrillation and flutter, atrioventricular nodal reentrant tachycardia) and ventricular tachycardias (eg, catecholamine-induced arrhythmias, digoxin toxicity).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Essential tremor:</b> Management of familial or hereditary essential tremor.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Management of hypertension. <b>Note:</b> Beta-blockers are <b>not</b> recommended as first-line therapy (ACC/AHA [Whelton 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: </b>Symptomatic treatment of hypertrophic cardiomyopathy with left ventricular outflow tract obstruction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention:</b> Prophylaxis of common migraine headache.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocardial infarction, early treatment and secondary prevention:</b> To reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pheochromocytoma:</b> As an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Proliferating infantile hemangioma (Hemangeol): </b>Treatment of proliferating infantile hemangioma requiring systemic therapy.</p></div>
<div class="block off-label drugH1Div" id="F25744560"><span class="drugH1">Use: Off-Label: Adult</span><p>Akathisia, antipsychotic-induced; Burns, moderate to severe (hypermetabolism modulation) (adjunctive agent); Performance anxiety disorder; Postural orthostatic tachycardia syndrome; Thyroid storm; Thyrotoxicosis; Tremor, lithium-induced, moderate to severe; Variceal hemorrhage prophylaxis</p></div>
<div class="block mst drugH1Div" id="F214948"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Propranolol may be confused with prasugrel, Pravachol, Propulsid.</p>
<p style="text-indent:-2em;margin-left:4em;">Inderal may be confused with Adderall, Enduron, Imdur, Imuran, Inderide, Isordil, Toradol.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Deralin [Australia, Israel] may be confused with Deptran brand name for doxepin [Australia].</p>
<p style="text-indent:-2em;margin-left:4em;">Inderal [Canada and multiple international markets], Inderal LA [US], and Inderal XL [US] may be confused with Indiaral brand name for loperamide [France] or Indamol brand name for indapamide [Italy].</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F214934"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major), CYP2C19 (minor), CYP2D6 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak)</p></div>
<div class="block dri drugH1Div" id="F214871"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May decrease the serum concentration of Propranolol. Alcohol (Ethyl) may increase the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: Propranolol may increase the serum concentration of BUPivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: Beta-Blockers may enhance the adverse/toxic effect of Cannabis. Specifically, the risk of hypoglycemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Charcoal, Activated: May diminish the therapeutic effect of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Moderate): May decrease the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Propranolol. Management: Use a lower initial propranolol dose and be more cautious during propranolol dose titration when combined with strong CYP1A2 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Beta-Blockers may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Propranolol may increase the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose. Increase monitoring for clinical response and adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Beta-Blockers may diminish the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Nasal): Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Oral Inhalation): Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine (Racemic): Beta-Blockers (Nonselective) may enhance the hypertensive effect of Epinephrine (Racemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may diminish the therapeutic effect of Etilefrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etofylline: Beta-Blockers may diminish the therapeutic effect of Etofylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers.  Management: Consider alternatives to either grass pollen allergen extract (5 grass extract) or beta-blockers in patients with indications for both agents.  Canadian product labeling specifically lists this combination as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guggul: May decrease the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Insulins. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Insulins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Beta-Blockers may diminish the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacidipine: May enhance the hypotensive effect of Propranolol. Lacidipine may increase the serum concentration of Propranolol. Propranolol may decrease the serum concentration of Lacidipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the bradycardic effect of Propranolol. Lasmiditan may diminish the therapeutic effect of Propranolol. Specifically, blood pressure may increase during coadministration.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): Propranolol may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Liraglutide: Propranolol may enhance the hypoglycemic effect of Liraglutide. Liraglutide may diminish the therapeutic effect of Propranolol. Specifically, the heart rate lowering effect of propranolol may be diminished. Propranolol may diminish the therapeutic effect of Liraglutide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: Beta-Blockers may enhance the adverse/toxic effect of Mavacamten. Specifically, negative inotropic effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mepivacaine: Propranolol may increase the serum concentration of Mepivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Beta-Blockers may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: May enhance the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: May increase the serum concentration of Propranolol. Propranolol may increase the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: May increase the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May enhance the bradycardic effect of Beta-Blockers. Reserpine may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rizatriptan: Propranolol may increase the serum concentration of Rizatriptan.  Management: Adults: limit rizatriptan dose to 5 mg (max of 3 doses per 24 hrs). Pediatric patients: if weight is 40 kg or more, limit rizatriptan to a single 5 mg dose per 24 hrs; do not combine if weight less than 40 kg. Rizatriptan oral film is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Beta-Blockers may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Sulfonylureas. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: Beta-Blockers may diminish the therapeutic effect of Tasimelteon.  Management: Consider avoiding nighttime administration of beta-blockers during tasimelteon therapy due to the potential for reduced tasimelteon efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Propranolol may increase the serum concentration of Thioridazine. Thioridazine may increase the serum concentration of Propranolol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">White Birch Allergen Extract: Beta-Blockers may enhance the adverse/toxic effect of White Birch Allergen Extract. Specifically, beta-blockers may reduce the effectiveness of beta-agonists that may be required to treat systemic reactions to white birch allergen extract. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zileuton: May increase the serum concentration of Propranolol.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F214902"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ethanol: Ethanol may increase or decrease plasma levels of propranolol. Reports are variable and have shown both enhanced as well as inhibited hepatic metabolism (of propranolol). Management: Caution advised with consumption of ethanol and monitor for heart rate and/or blood pressure changes.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Food: Propranolol serum levels may be increased if taken with food. Protein-rich foods may increase bioavailability; a change in diet from high carbohydrate/low protein to low carbohydrate/high protein may result in increased oral clearance. Management: Tablets (immediate release) should be taken on an empty stomach. Capsules (extended release) may be taken with or without food, but be consistent with regard to food.</p></div>
<div class="block rep_considerations drugH1Div" id="F56628714"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Propranolol is generally not a preferred agent for use in pregnant patients (ACC/AHA [Whelton 2018]; ACOG 2019); however, use may be considered (SOGC [Magee 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Propranolol is approved for prevention of migraines. In general, preventive treatment for migraine in patients trying to become pregnant should be avoided. Options for patients planning a pregnancy should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data and needs of the patient should pregnancy occur. A gradual discontinuation of preventive medications is generally preferred when the decision is made to stop treatment prior to conception (ACOG 2022; AHS [Ailani 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Erectile dysfunction and male impotence are noted in product labeling following use of propranolol. As a class, outcomes from available studies evaluating beta-blockers and sexual dysfunction are inconsistent, and the negative effects on erectile function and libido are considered controversial. A clear relationship between use of beta-blockers and erectile dysfunction has not been established. Hypertension itself is associated with erectile dysfunction. Patients on a beta-blocker presenting with sexual dysfunction should be evaluated for underlying disease (Farmakis 2021; Levine 2012; Semet 2017; Terentes-Printzios 2022; Viigimaa 2020).</p></div>
<div class="block pri drugH1Div" id="F214888"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Propranolol crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Exposure to beta-blockers during the third trimester of pregnancy may increase the risk for bradycardia, hypoglycemia, hypotension, and respiratory depression in the neonate. Newborns should be monitored and managed accordingly. If maternal use of a beta-blocker is needed, monitor fetal growth during pregnancy; monitor the newborn for 48 hours after delivery for bradycardia, hypoglycemia, and respiratory depression (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetics of propranolol are not significantly changed by pregnancy (Livingstone 1983; O'Hare 1984; Rubin 1987; Smith 1983).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of hypertension is initiated during pregnancy, agents other than propranolol may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]); however, use may be considered (SOGC [Magee 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Propranolol may be used for the treatment of maternal ventricular arrhythmias, atrial fibrillation/atrial flutter, or supraventricular tachycardia during pregnancy; consult current guidelines for specific recommendations (ACC/AHA/HRS [Page 2016]; ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Propranolol is recommended for use in controlling hypermetabolic symptoms of thyrotoxicosis in pregnancy (ATA [Alexander 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">In general, preventive treatment for migraine should be avoided during pregnancy. Options for pregnant patients should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data, the potential for adverse maternal and fetal events, and needs of the patient (ACOG 2022; AHS [Ailani 2021]). If preventive therapy is needed, beta-blockers may be considered (ACOG 2022). Based on available data, propranolol may be used if prophylaxis of migraine is needed in pregnant patients; it should be discontinued 2 to 3 days prior to delivery to decrease the risk of adverse events to the fetus/neonate and potential reductions in uterine contraction (CHS [Pringsheim 2012]).</p></div>
<div class="block brc drugH1Div" id="F214889"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Propranolol and its inactive metabolites are present in breast milk (Smith 1983).</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of propranolol in breast milk are available from 3 lactating patients 1-week postpartum receiving propranolol for hypertension. Breast milk was sampled ~3, 4, 6, and 8 hours after the maternal dose. The first 2 patients received propranolol 1.2 mg/kg/day and the third received propranolol 2.6 mg/kg/day. The highest propranolol milk concentration was 74.9 ng/mL observed in the first patient ~3 hours after the dose. The lowest propranolol milk concentration was 13.5 ng/mL in the second patient, observed ~8 hours after the dose. The overall half-life of propranolol in breast milk was 6.5 ± 3.4 hours. In comparison, the overall half-life in the maternal plasma was 2.6 ± 1.2 hours (Smith 1983). Peak milk concentrations are reported to occur between 2 to 3 hours after an oral dose (Bauer 1979).</p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia was reported in an infant exposed to propranolol via breast milk (Soussan 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">In general, preventive treatment for migraine in lactating patients should be avoided. When needed, therapy should be individualized considering the available safety data and needs of the patient (AHS [Ailani 2021]). Based on available data, propranolol may be used if prophylaxis of migraine is needed in lactating patients (CHS [Pringsheim 2012]).</p>
<p style="text-indent:-2em;margin-left:2em;">When used for hypertension, propranolol is compatible for use in patients who are breastfeeding (ACOG 2019; ESC [Cífková 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">In general, propranolol may be compatible with breastfeeding when used at usual doses. Breastfeeding infants should be monitored for bradycardia, cyanosis, and hypoglycemia (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F214890"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Tablets (immediate release) should be taken on an empty stomach; capsules (extended release) may be taken with or without food, but should always be taken consistently (with food or on an empty stomach). Hemangeol should be administered during or right after a feeding to reduce the risk of hypoglycemia; skip dose if child is not eating or is vomiting.</p></div>
<div class="block mop drugH1Div" id="F214875"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Acute cardiac treatment: ECG, heart rate, and blood pressure.</p>
<p style="text-indent:-2em;margin-left:2em;">Hypertension: Blood pressure, heart rate.</p>
<p style="text-indent:-2em;margin-left:2em;">Mental alertness; signs and symptoms of bronchospasm in patients with existing bronchospastic disease; serum glucose (in patients with diabetes).</p>
<p style="text-indent:-2em;margin-left:2em;">Proliferating infantile hemangioma (Hemangeol): Monitor heart rate and blood pressure for 2 hours after initiation or dose increases.</p></div>
<div class="block rer drugH1Div" id="F57948546"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Blood pressure goal: May vary depending on clinical conditions, different clinical practice guidelines, and expert opinion. Refer to "Clinical Practice Guidelines" for specific treatment goals.</p></div>
<div class="block pha drugH1Div" id="F214865"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nonselective beta-adrenergic blocker (class II antiarrhythmic); competitively blocks response to beta<sub>1</sub>- and beta<sub>2</sub>-adrenergic stimulation which results in decreases in heart rate, myocardial contractility, blood pressure, and myocardial oxygen demand. Nonselective beta-adrenergic blockers (propranolol, nadolol) reduce portal pressure by producing splanchnic vasoconstriction (beta<sub>2</sub> effect) thereby reducing portal blood flow. </p></div>
<div class="block phk drugH1Div" id="F214884"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Beta-blockade: Oral: 1 to 2 hours; IV: ≤5 minutes; Peak effect: Hypertension: A few days to several weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Immediate release: 6 to 12 hours; Extended-release formulations: ~24 to 27 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid and complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 4 L/kg (adults); crosses the blood-brain barrier.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Newborns: 68%; Adults: ~90% (S-isomer primarily to alpha-1 acid glycoprotein; R-isomer primarily to albumin).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive first-pass effect, hepatically metabolized to active and inactive compounds; the 3 main metabolic pathways include: Aromatic hydroxylation (primarily 4-hydroxylation), N-dealkylation followed by further side-chain oxidation and direct glucuronidation; the 4 primary metabolites include: Propranolol glucuronide, naphthyloxylactic acid, and sulfate and glucuronic acid conjugates of 4-hydroxy propranolol; <b>Note:</b> Aromatic hydroxylation is catalyzed primarily by isoenzyme CYP2D6; side chain oxidation is mainly via CYP1A2, but also CYP2D6; 4-hydroxypropranolol possesses beta-adrenergic receptor blocking activity and is a weak inhibitor of CYP2D6.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~25% reaches systemic circulation due to high first-pass metabolism; oral bioavailability may be increased in children with Down syndrome; protein-rich foods increase bioavailability by ~50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: GA 23 to 26 weeks: 13.8 ± 3.9 hours, GA 27 to 34 weeks: 15.7 ± 5.1 hours, GA 35 to 42 weeks: 15.5 ± 0.7 hours (Filippi 2013); Infants (35 to 150 days of age): Median 3.5 hours; Children: 3.9 to 6.4 hours; Adults: Immediate-release formulation: 3 to 6 hours; Extended-release formulations: 8 to 10 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Immediate release: Neonates: 2.6 ± 0.9 hours (Filippi 2013); Infants: ≤2 hours (Hemangeol); Adults: 1 to 4 hours; Extended-release capsule (Inderal XL, InnoPran XL): Adults: 12 to 14 hours; Long-acting capsule (Inderal LA): Adults: 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Metabolites are excreted primarily in urine (96% to 99%); &lt;1% excreted in urine as unchanged drug.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F214891"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo propranolol | Bedranol | Cardilol | Corbeta | Inderal</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Inderal | Nedis | Oposim | Propader | Propalong | Propaneitor | Propanolol northia | Propanolol vannier | Propranolol gador | Propranolol northia</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Inderal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo propranolol | Deralin | Inderal</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Adlock | Betacap-tr | Cardilol | Cardinol | Indever | Presoral | Propranol | Propranolol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Inderal | Propranolol Eurogenerics | Propranolol teva generics belgium</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Propranolol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Inderal | Obsidan | Propranolol | Propranolol accord | Propranolol actavis</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Amprax | Antitensin | Cardbloc | Cardix | Cloridrato de propranolol | Farmanguinhos propranolol | Furp propranolol | Hipernolol | Inderal | Iquego propanolol | Iquego propranolol | Lfm propranolol | Lqfex propranolol | Pharnolol | Polol | Pradinolol | Pranolal | Pressoflux | Promangiol | Pronol | Pronolol | Propacor | Propalol | Propanolon | Propanox | Proparil | Propramed | Propranolil | Propranolol | Propranolom | Propratec | Rebaten la | Sanpronol | Uni propralol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Betaprol | Inderal | Propranolol helvepharm | Propranolol retard zentiva | Propranolol zentiva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Coriodal | Propanolol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bai er luo | Hang da lai | Propranolol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Artensol | Inderal | Propamox | Propanolol | Propranolol | Propranolol mk | Servanolol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Obsidan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Beta Timelets | Beta-tablinen | Efektolol | Elbrol | Hemangiol | Inderal | Indobloc | Obsidan | Propabloc | Prophylux | Propra | Propranolol 3mm | Propranolol al | Propranolol CT | Propranolol Gry | Propranolol Sandoz | Propranur</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Propal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cardin | Corapront | Cymaprolol | Inderal | Indupres | Propa | Propanil | Propanolol | Propanolol if | Propanolol Inmenol | Propanolol Lam | Propra</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Inderal | Propanolol | Propranolol Genfar | Protolif</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Anaprilin | Dociton | Inderal | Obsidan | Propra | Propral | Propranolol | Propranolol accord | Propranolol ns</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Inderal | Indolol | Mayestrotense | Prolol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Propranolol accord | Propranolol aurovitas | Propranolol kern | Sumial</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Propranolol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Inderal | Oriloc | Propral | Propranolol accord | Proprasal | Ranoprin | Reducor</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Adrexan | Avlocardyl | Beprane | Chlorhydrate de propranolol | Dociton | Hemangiol | Hemipralon lp | Karnodyl | Propranolol accord | Propranolol acetlab | Propranolol arrow | Propranolol biogaran | Propranolol dci | Propranolol eg | Propranolol ratiopharm</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Angilol | Apsolol | Bedranol | Berkolol | Beta prograne | Cardinol | Dupromex | Half beta prograne | Half Inderal | Inderal | Inderal La | Lopranol | Probeta la | Propanix | Propatard | Propranolol | Propranolol Almus | Propranolol berk | Propranolol cox | Propranolol kent | Propranolol Sandoz | Rapranol | Sloprolol | Syprol | Unilol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dociton | Hemangiol | Inderal</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Angilol | Antarol | Apo propranolol | Becardin | Betapress | Hopranolol | Inderal | Inpanol | Pralol | Prolol | Pronolol | Propranolol | Propranolol actavis | Qualipanol | Synolol | Syntonol | Uni-Panolol</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Propranolol Lek | Propranolol Sandoz</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Huma-pronol | Inderal | Propranolol | Stobetin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Blocard | Farmadral | Inderal | Propadex | Propranolol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Berkolol | Beta prograne | Inderal | Propranolol | Syprol | Tiperal</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Deralin | Prolol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alprolone | Arminol | Betabloc | Betacap | Betacap-tr | Betanol | Betanol tr | Betapro | Betapro sr | Cardiplan | Carenol | Ciplar | Ciplar la | Corbeta | Hd | Inderal | Lol | Manoprolol | Mibeta | Migrabeta | Nigrain | Nigrain tr | Norten | Oslol | Pilol | Plol | Ponol | Pop tr | Prolar | Prolar sr | Prolol | Promotil TR | Pronate | Pronol | Prop 10 | Propal | Properol | Propranolol | Provanol | Rapanol | Signolol | Tenpose | Theolar | Trilol | Walbeta | Walbeta LA</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Becardin | Pranolawa | Procard</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Inderal | Inderal graduale</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Atensin | Inderal | Indicardin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Aideitorol | Aideitorol tsuruhara | Angiton | Caridorol | Defranol | Hemangiol | Herzbase | Herzul | Inderal | Jaxonin | Kemi | Mentories | Normotens | Poical | Propanolol hydrochloride | Proprano.hcl sv towa | Propranolol HCL | Propranolol hydrochloride tsuruhara | Pylapron | Rapynogen | Sawatal | Shinpral | Sorasilol | Tag | Tesnol</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bedranol | Carderal | Hipertol | Inderal | Propranolol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Caoderal | Hemangiol | Indenol | Inderal | Inderal La | Indesol | Pranol | Prenal | Pronil | Pronol | Tepra</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Inderal</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo propranolol | Bedranol | Dociton | Hemangiol | Inderal | Probetol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Allapinin | Anaprilin | Apo propranolol | Inderal | Obsidan | Propra | Propranolol | Propranolol accord | Propranolol al | Propranolol arena | Propranolol CT | Stobetin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Inderal | Propranolol Eurogenerics</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Allapinin | Anaprilin | Apo propranolol | Inderal | Obsidan | Propranolol</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Avlocan | Avlocardyl</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acifol | Colliprol | Hemeli | Inderal | Inderalici | Pranidol | Pranoral | Prochor | Propalem | Propanolol | Propanolol boehringer | Sintaser</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Antarol | Apo propranolol | Corbeta | Hipranol | Hopranolol | Inderal | Indon | Inpanol | Nalol | Norbeat | Pronolol | Propa | Propranolol | Setpanol | Triopranol</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Eden propranolol | Exus propranolol | Multichris propranolol | Propraderel | Propranolol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Inderal | Propranol Hcl | Propranolol HCL | Propranolol hcl A | Propranolol hcl Alpharma | Propranolol hcl cf | Propranolol Hcl PCH | Propranolol hcl ratiopharm | Propranolol hcl sandoz | Propranolol hcl teva retard</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dociton | Hemangiol | Inderal | Pranolol | Propal retard | Propranolol | Propranolol accord | Propranolol teva | Syprol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Angilol | Cardinol | Deralin | Inderal | Propranolol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Carpronol | Inderal | Propanolol | Propranolol | Propranolol HCL</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Asterol | Duranol | Inderal | Indirin | Migradol | Oranol | Phanerol | Propranolol-phoenix | Stabeta | Valupan</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Betablock | Betanol | Cardinol | Cardioset | Half beta-prograne | Hyporide-la | Hyprol | Inderal | Opinol | Oprinol | Pranodal | Pronol | Propranolol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Propranolol | Propranolol accord | Syprol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Betachron | Hemangeol | Inderal | Innopran | Propranolol HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Corpendol | Dociton | Hemangiol | Inderal | Propranolol | Propranolol accord | Propranolol arena</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Propanolol dutriec | Propanolol LCh | Propayerst | Propranolol Clorhidrato mintlab | Propranolol gador</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Apo-Propranolol | Dociton | Inderal</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Propranolol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Allapinin | Anaprilin | Apo propranolol | Gemangiol | Inderal | Novo pranol | Obsidan | Propranolol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo propranolol | Inderal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Inderal | Propranolol | Propranolol 2care4 | Propranolol accord | Propranolol ebb</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Angilol | Apo propranolol | Betascan | Deralin | Inderal | Inpanol | Nalol | Pronol | Propa | Propanol | Propranolol | Synolol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol | Inderal | Propranolol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Hemangiol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alperol | Annalol | Apo propranolol | Atensin | Beloc | Berkolol | Beta-b | Betalol | Betapress | Cardenol | Chinnolol | Derinol | Emforal | Idelol | Inderal | Inderal La | Inderan | Inmadal | Inmedal | Innoral | Inolol | Normpress | P-parol | Palon | Panol | Perlol | Pipprolol | Planol | Pralol | Prodol | Pronalol | Pronol | Pronol-f | Pronosil | Propanol | Prophalol | Propranolol | Proral | Ranolol | Servanolol | Sinolol | Syntonol | Zinderan</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Avlocardyl | Inderal | Normocardil | Propranolol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dideral | Hemangiol | Inderal | Proderal</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Adreblock | Anderan | Cadioral | Carderal | Cardiolol | Cardolol | Chierhsin | Cinderal | Dispec | Duranol | Endure | Heloprop | Hemalol | Hersun | Indal | Inderal | Kidoral | Laining | Lideral | Pranol | Pranolol | Pronalol | Propra | Propralol | Propranol | Propranolol | Proranol | Prosanol | Sinal | Sinlihaul | Sudenol | Susin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Anaprilin | Apo propranolol | Inderal | Obsidan | Propranolol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Hyper | Nolol | Propan | Propranolol | Renpress</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alligor | Ciperpina | Inderal | Opranol | Propanol | Propanolol | Propranol | Propranolol gador</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Algoren | Docitral | Inderal | Inderal zeneca | Propanolol | Propranolol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Inderal | Inderal La | Indoblok | Prodorol | Pur bloka | Purbloka | Rolab-propranolol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Hopranolol | Inderal | Kamcard | Propranolol | Pur bloka | Rexigen</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Propranolol | Rexigen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-2877708">
<a name="2877708"></a>Adler LA, Angrist B, Peselow E, Corwin J, Maslansky R, Rotrosen J. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. <i>Br J Psychiatry</i>. 1986;149:42-45. doi: 10.1192/bjp.149.1.42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2877708/pubmed" id="2877708" target="_blank">2877708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8290678">
<a name="8290678"></a>Adler LA, Peselow E, Rosenthal M, Angrist B. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis. <i>Psychopharmacol Bull.</i> 1993;29(2):283-286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/8290678/pubmed" id="8290678" target="_blank">8290678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29085724">
<a name="29085724"></a>Agarwal S, Sharma A, Maria A. Diffuse neonatal hemangiomatosis presenting as congestive heart failure. <i>Dermatol Pract Concept</i>. 2017;7(3):66-69. doi:10.5826/dpc.0703a15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/29085724/pubmed" id="29085724" target="_blank">29085724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28056690">
<a name="28056690"></a>Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. <i>Thyroid</i>. 2017;27(3):315-389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/28056690/pubmed" id="28056690" target="_blank">28056690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death [published correction appears in: <i>Circulation</i>. 2018;138(13):e419-e420.]. <i>Circulation</i>. 2018;138(13):e272-e391. doi: 10.1161/CIR.0000000000000549.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32258322">
<a name="32258322"></a>Al-Rwebah H, Alkhodair R, Al-Khenaizan S. Propranolol-induced hyperkalemia in the management of infantile hemangioma. <i>JAAD Case Rep</i>. 2020;6(4):359-361. doi:10.1016/j.jdcr.2020.01.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/32258322/pubmed" id="32258322" target="_blank">32258322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Anderson.1">
<a name="Anderson.1"></a>Anderson RH, Baker EJ, Penny DJ, et al, eds. <i>Paediatric Cardiology</i>. 3rd ed. Philadelphia, PA: Saunders Elsevier; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apo-Propranolol.1">
<a name="Apo-Propranolol.1"></a>Apo-Propranolol [product monograph]. Toronto, Ontario, Canada: Apo Tex Inc; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23616163">
<a name="23616163"></a>Arnold AC, Okamoto LE, Diedrich A, et al. Low-dose propranolol and exercise capacity in postural tachycardia syndrome: a randomized study. <i>Neurology</i>. 2013;80(21):1927-1933. doi:10.1212/WNL.0b013e318293e310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23616163/pubmed" id="23616163" target="_blank">23616163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [published corrections appear in <i>Circulation</i>. 2011;124(5):e175; <i>Circulation</i>. 2011;123(21):e616; <i>Circulation</i>. 2016;133(24):e71]. <i>Circulation.</i> 2011;123(21):2434-2506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10766701">
<a name="10766701"></a>Ashikaga H, Abreu R, Schneider RF. Propanolol administration in a patient with thyroid storm. <i>Ann Intern Med</i>. 2000;132(8):681-682. doi:10.7326/0003-4819-132-8-200004180-00029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/10766701/pubmed" id="10766701" target="_blank">10766701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16120482">
<a name="16120482"></a>Ashrafi MR, Shabanian R, Zamani GR, Mahfelati F. Sodium valproate versus propranolol in paediatric migraine prophylaxis. <i>Eur J Paediatr Neurol</i>. 2005;9(5):333-338.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/16120482/pubmed" id="16120482" target="_blank">16120482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12447861">
<a name="12447861"></a>Bañares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i>. 2002;36(6):1367-1373. doi: 10.1053/jhep.2002.36947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/12447861/pubmed" id="12447861" target="_blank">12447861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23796325">
<a name="23796325"></a>Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. <i>Int J Cardiol</i>. 2013;168(4):3572-3579. doi:10.1016/j.ijcard.2013.05.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23796325/pubmed" id="23796325" target="_blank">23796325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25282062">
<a name="25282062"></a>Barton AL, Moffett BS, Valdes SO, Miyake C, Kim JJ. Efficacy and safety of high-dose propranolol for the management of infant supraventricular tachyarrhythmias. <i>J Pediatr</i>. 2015;166(1):115-118.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/25282062/pubmed" id="25282062" target="_blank">25282062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-425926">
<a name="425926"></a>Bauer JH, Pape B, Zajicek J, et al. Propranolol in human plasma and breast milk. <i>Am J Cardiol</i>. 1979;43(4):860-862.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/425926/pubmed" id="425926" target="_blank">425926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bernstein.1">
<a name="Bernstein.1"></a>Bernstein D. Cyanotic congenital heart disease: Lesions associated with decreased pulmonary blood flow. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020: chap. 457.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7038157">
<a name="7038157"></a>Beta-Blocker Heart Attack Trial (BHAT) Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. <i>JAMA</i>. 1982;247(12):1707-1714. doi: 10.1001/jama.1982.03320370021023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/7038157/pubmed" id="7038157" target="_blank">7038157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23303551">
<a name="23303551"></a>Bonfert M, Straube A, Schroeder AS, Reilich P, Ebinger F, Heinen F. Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. <i>Neuropediatrics</i>. 2013;44(1):3-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23303551/pubmed" id="23303551" target="_blank">23303551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35150504">
<a name="35150504"></a>Boyraz RK, Şahan E, Kırpınar İ. A case report with a mini-review of the literature on the overeating and weight gain due to propranolol. <i>Psychiatr Danub</i>. 2021;33(Suppl 13):330-332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/35150504/pubmed" id="35150504" target="_blank">35150504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6120650">
<a name="6120650"></a>Brantigan CO, Brantigan TA, Joseph N. Effect of beta blockade and beta stimulation on stage fright. <i>Am J Med</i>. 1982;72(1):88-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6120650/pubmed" id="6120650" target="_blank">6120650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Braverman.2013">
<a name="Braverman.2013"></a>Braverman L, Cooper D. <i>Werner &amp; Ingbar's The Thyroid: A Fundamental and Clinical Text</i>. 10th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29746858">
<a name="29746858"></a>Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. <i>J Urol</i>. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/29746858/pubmed" id="29746858" target="_blank">29746858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cameron.1">
<a name="Cameron.1"></a>Cameron P, Jelinek G, Everitt I, et al. <i>Textbook of Paediatric Emergency Medicine</i>. 2nd ed. Churchill Livingstone Elsevier; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29699616">
<a name="29699616"></a>Chatzidou S, Kontogiannis C, Tsilimigras DI, et al. Propranolol versus metoprolol for treatment of electrical storm in patients with implantable cardioverter-defibrillator.<i> J Am Coll Cardiol.</i> 2018;71(17):1897-1906. doi: 10.1016/j.jacc.2018.02.056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/29699616/pubmed" id="29699616" target="_blank">29699616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31931932">
<a name="31931932"></a>Cheema SA, Ahmed UT, Nasir H, Dogar SR, Mustafa Z. Effects of propranolol in accelerating wound healing and attenuation of hypermetabolism in adult burn patients. <i>J Coll Physicians Surg Pak</i>. 2020;30(1):46-50. doi:10.29271/jcpsp.2020.01.46<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/31931932/pubmed" id="31931932" target="_blank">31931932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12918133">
<a name="12918133"></a>Cheng JW, Zhu L, Gu MJ, Song ZM. Meta-analysis of propranolol effects on gastrointestinal hemorrhage in cirrhotic patients. <i>World J Gastroenterol.</i> 2003;9(8):1836-1839.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/12918133/pubmed" id="12918133" target="_blank">12918133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9833593">
<a name="9833593"></a>Choudhury RP, MacDermot J. Heart failure in thyrotoxicosis, an approach to management. <i>Br J Clin Pharmacol</i>. 1998;46(5):421-424. doi:10.1046/j.1365-2125.1998.00804.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/9833593/pubmed" id="9833593" target="_blank">9833593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2713197">
<a name="2713197"></a>Clark DJ, Chan KC, Gibbs JL. Propranolol induced bradycardia in tetralogy of Fallot. <i>Br Heart J</i>. 1989;61(4):378-379. doi:10.1136/hrt.61.4.378<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2713197/pubmed" id="2713197" target="_blank">2713197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18654082">
<a name="18654082"></a>Cocco G. Erectile dysfunction after therapy with metoprolol: the Hawthorne effect. <i>Cardiology</i>. 2009;112(3):174-177. doi:10.1159/000147951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/18654082/pubmed" id="18654082" target="_blank">18654082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5653028">
<a name="5653028"></a>Conway N, Seymour J, Gelson A. Cardiac failure in patients with valvar heart disease after use of propranolol to control atrial fibrillation. <i>Br Med J</i>. 1968;2(5599):213-214. doi:10.1136/bmj.2.5599.213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/5653028/pubmed" id="5653028" target="_blank">5653028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25750228">
<a name="25750228"></a>Correia MF, Maria AT, Prado S, Limbert C. Neonatal thyrotoxicosis caused by maternal autoimmune hyperthyroidism. <i>BMJ Case Rep</i>. 2015;2015:bcr2014209283. doi:10.1136/bcr-2014-209283<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/25750228/pubmed" id="25750228" target="_blank">25750228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15579370">
<a name="15579370"></a>Covar RA, Macomber BA, Szefler SJ. Medications as asthma triggers. <i>Immunol Allergy Clin North Am</i>. 2005;25(1):169-190. doi:10.1016/j.iac.2004.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/15579370/pubmed" id="15579370" target="_blank">15579370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24898244">
<a name="24898244"></a>Cristofori F, Thapar N, Saliakellis E, et al. Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome. <i>Aliment Pharmacol Ther</i>. 2014;40(3):309-317. doi:10.1111/apt.12822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24898244/pubmed" id="24898244" target="_blank">24898244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3009050">
<a name="3009050"></a>Croft CH, Rude RE, Gustafson N, et al. Abrupt withdrawal of beta-blockade therapy in patients with myocardial infarction: effects on infarct size, left ventricular function, and hospital course. <i>Circulation</i>. 1986;73(6):1281-1290. doi:10.1161/01.cir.73.6.1281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/3009050/pubmed" id="3009050" target="_blank">3009050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969714">
<a name="1969714"></a>Dahlöf C, Dimenäs E. Side effects of beta-blocker treatments as related to the central nervous system. <i>Am J Med Sci</i>. 1990;299(4):236-244. doi:10.1097/00000441-199004000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1969714/pubmed" id="1969714" target="_blank">1969714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dalal.1">
<a name="Dalal.1"></a>Dalal AS, Van Hare GF. Disturbances of rate and rhythm of the heart. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020: chap. 462.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26416931">
<a name="26416931"></a>Darrow DH, Greene AK, Mancini AJ, et al. Diagnosis and management of infantile hemangioma.<i> Pediatrics</i>. 2015;136(4):e1060-1104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/26416931/pubmed" id="26416931" target="_blank">26416931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21601311">
<a name="21601311"></a>de Graaf M, Breur JMPJ, Raphaël MF, Vos M, Breugem CC, Pasmans SGMA. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. <i>J Am Acad Dermatol</i>. 2011;65(2):320-327. doi:10.1016/j.jaad.2010.06.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/21601311/pubmed" id="21601311" target="_blank">21601311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21256454">
<a name="21256454"></a>Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. <i>Lancet Neurol</i>. 2011;10(2):148-161. doi: 10.1016/S1474-4422(10)70322-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/21256454/pubmed" id="21256454" target="_blank">21256454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31633896">
<a name="31633896"></a>Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the prevention of acute exacerbations of COPD. <i>N Engl J Med</i>. 2019;381(24):2304-2314. doi:10.1056/NEJMoa1908142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/31633896/pubmed" id="31633896" target="_blank">31633896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23266923">
<a name="23266923"></a>Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. <i>Pediatrics</i>. 2013;131(1):128-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23266923/pubmed" id="23266923" target="_blank">23266923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9734990">
<a name="9734990"></a>“Drugs for Pediatric Emergencies. Committee on Drugs, Committee on Drugs, 1996 to 1997, Liaison Representatives, and AAP Section Liaisons,” <i>Pediatrics</i>, 1998, 101(1):E13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/9734990/pubmed" id="9734990" target="_blank">9734990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31775749">
<a name="31775749"></a>Dungan K, Merrill J, Long C, Binkley P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. <i>Cardiovasc Diabetol</i>. 2019;18(1):163. doi:10.1186/s12933-019-0967-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/31775749/pubmed" id="31775749" target="_blank">31775749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897781">
<a name="2897781"></a>Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. <i>Am J Cardiol</i>. 1988;61(15):1219-1222. doi:10.1016/0002-9149(88)91158-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2897781/pubmed" id="2897781" target="_blank">2897781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22633628">
<a name="22633628"></a>Eidlitz-Markus T, Dlugatch Y, Haimi-Cohen Y, Goldberg-Stern H, Zeharia A. Nonpharmacologic treatment of migraine with low-dose propranolol or amitriptyline. <i>Pediatr Neurol</i>. 2012;46(6):345-349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/22633628/pubmed" id="22633628" target="_blank">22633628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2652097">
<a name="2652097"></a>Farine M, Arbus G. Management of hypertensive emergencies in children. <i>Pediatr Emerg Care.</i> 1989;5(1):51-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2652097/pubmed" id="2652097" target="_blank">2652097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33945044">
<a name="33945044"></a>Farmakis IT, Pyrgidis N, Doundoulakis I, Mykoniatis I, Akrivos E, Giannakoulas G. Effects of major antihypertensive drug classes on erectile function: a network meta-analysis.<i> Cardiovasc Drugs</i>
<i>Ther</i>. Published online May 4, 2021. doi:10.1007/s10557-021-07197-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/33945044/pubmed" id="33945044" target="_blank">33945044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19725596">
<a name="19725596"></a>Ferrara J, Jankovic J. Epidemiology and management of essential tremor in children. <i>Paediatr Drugs</i>. 2009;11(5):293-307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/19725596/pubmed" id="19725596" target="_blank">19725596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31046186">
<a name="31046186"></a>Ferreira JJ, Mestre TA, Lyons KE, et al. MDS evidence-based review of treatments for essential tremor. <i>Mov Disord</i>. 2019;34(7):950-958. doi:10.1002/mds.27700<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/31046186/pubmed" id="31046186" target="_blank">31046186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al, “Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [published correction appears in <i>Circulation. </i>2014;126(16):e463]. <i>Circulation. </i>2012;126(25):3097-3137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23205867">
<a name="23205867"></a>Filippi L, Cavallaro G, Fiorini P, et al. Propranolol concentrations after oral administration in term and preterm neonates. <i>J Matern Fetal Neonatal Med</i>. 2013;26(8):833-840. doi:10.3109/14767058.2012.755169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23205867/pubmed" id="23205867" target="_blank">23205867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10775081">
<a name="10775081"></a>Flynn JT. Neonatal hypertension: diagnosis and management. <i>Pediatr Nephrol</i>. 2000;14(4):332-341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/10775081/pubmed" id="10775081" target="_blank">10775081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17137886">
<a name="17137886"></a>Flynn JT, Daniels SR. Pharmacologic treatment of hypertension in children and adolescents. <i>J Pediatr</i>. 2006;149:746-754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/17137886/pubmed" id="17137886" target="_blank">17137886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. <i>Pediatrics</i>. 2017;140(3).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18617067">
<a name="18617067"></a>Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. <i>J Am Coll Cardiol</i>. 2008;52(3):190-199. doi:10.1016/j.jacc.2008.03.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/18617067/pubmed" id="18617067" target="_blank">18617067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20067434">
<a name="20067434"></a>Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. <i>Curr Med Res Opin</i>. 2010;26(3):615-629. doi:10.1185/03007990903533681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/20067434/pubmed" id="20067434" target="_blank">20067434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6867180">
<a name="6867180"></a>Foster CA and Aston SJ, “Propranolol-Epinephrine Interaction: A Potential Disaster,” <i>Plast Reconstr Surg</i>, 1983, 72(1):74-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6867180/pubmed" id="6867180" target="_blank">6867180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32298480">
<a name="32298480"></a>Frieden IJ, Püttgen KB, Drolet BA, et al. Management of infantile hemangiomas during the COVID pandemic. <i>Pediatr Dermatol</i>. 2020;37(3):412-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/32298480/pubmed" id="32298480" target="_blank">32298480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2883874">
<a name="2883874"></a>Frishman WH. Beta-adrenergic blocker withdrawal. <i>Am J Cardiol</i>. 1987;59(13):26F-32F. doi:10.1016/0002-9149(87)90038-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2883874/pubmed" id="2883874" target="_blank">2883874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2895072">
<a name="2895072"></a>Frishman WH. Beta-adrenergic receptor blockers. Adverse effects and drug interactions. <i>Hypertension</i>. 1988;11(3 Pt 2):II21-II29. doi:10.1161/01.hyp.11.3_pt_2.ii21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2895072/pubmed" id="2895072" target="_blank">2895072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37046020">
<a name="37046020"></a>Fu R, Zou Y, Wu Z, et al. Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population. <i>Sci Rep</i>. 2023;13(1):5956. doi:10.1038/s41598-023-33105-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/37046020/pubmed" id="37046020" target="_blank">37046020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fuhrman.1">
<a name="Fuhrman.1"></a>Fuhrman B, Zimmerman J, Carcillo J, et al. <i>Pediatric Critical Care</i>. 4th ed. Philadelphia Pennsylvania: Elsevier Mosby; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27786365">
<a name="27786365"></a>Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases [published correction appears in <i>Hepatology</i>. 2017;66(1):304]. <i>Hepatology</i>. 2017;65(1):310-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/27786365/pubmed" id="27786365" target="_blank">27786365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6164284">
<a name="6164284"></a>Garson A Jr, Gillette PC, and McNamara DG. Propranolol: The preferred palliation for tetralogy of fallot. <i>Am J Cardiol</i>. 1981;47(5):1098-1104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6164284/pubmed" id="6164284" target="_blank">6164284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27659028">
<a name="27659028"></a>Garzon MC, Epstein LG, Heyer GL, et al. PHACE syndrome: consensus-derived diagnosis and care recommendations. <i>J Pediatr</i>. 2016;178:24-33.e2. doi:10.1016/j.jpeds.2016.07.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/27659028/pubmed" id="27659028" target="_blank">27659028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7615481">
<a name="7615481"></a>Gelenberg AJ, Jefferson JW. Lithium tremor. <i>J Clin Psychiatry</i>. 1995;56(7):283-287.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/7615481/pubmed" id="7615481" target="_blank">7615481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8956349">
<a name="8956349"></a>Gleiter CH, Deckert J. Adverse CNS-effects of beta-adrenoceptor blockers. <i>Pharmacopsychiatry</i>. 1996;29(6):201-211. doi:10.1055/s-2007-979572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/8956349/pubmed" id="8956349" target="_blank">8956349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2890682">
<a name="2890682"></a>Greenberger PA, Meyers SN, Kramer BL, Kramer BL. Effects of beta-adrenergic and calcium antagonists on the development of anaphylactoid reactions from radiographic contrast media during cardiac angiography. <i>J Allergy Clin Immunol</i>. 1987;80(5):698-702. doi:10.1016/0091-6749(87)90290-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2890682/pubmed" id="2890682" target="_blank">2890682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Habeshian.1">
<a name="Habeshian.1"></a>Habeshian KA, Choi H. Dermatology. In: Boardman J, Groves A, Ramasethu J, eds. <i>Avery &amp; MacDonald's Neonatology - Pathophysiology and Management of the Newborn</i>. 8th ed. Lippincott Williams &amp; Wilkins; 2021: chap. 61.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6799077">
<a name="6799077"></a>Hansteen V, Møinichen E, Lorentsen E, et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. <i>Br Med J (Clin Res Ed).</i> 1982;284(6310):155-160. doi: 10.1136/bmj.284.6310.155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6799077/pubmed" id="6799077" target="_blank">6799077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1244260">
<a name="1244260"></a>Harrison DC, Alderman EL. Editorial: Discontinuation of propranolol therapy. Cause of rebound angina pectoris and acute coronary events. <i>Chest</i>. 1976;69(1):1-2. doi:10.1378/chest.69.1.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1244260/pubmed" id="1244260" target="_blank">1244260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6871565">
<a name="6871565"></a>Hartley LR, Ungapen S, Davie I, Spencer DJ. The effect of beta adrenergic blocking drugs on speakers' performance and memory.<i> Br J Psychiatry</i>. 1983;142:512-517. doi: 10.1192/bjp.142.5.512.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6871565/pubmed" id="6871565" target="_blank">6871565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36243426">
<a name="36243426"></a>Hasbani DJ, Hamie L. Infantile Hemangiomas. <i>Dermatol Clin</i>. 2022;40(4):383-392. doi:10.1016/j.det.2022.06.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/36243426/pubmed" id="36243426" target="_blank">36243426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Hegenbarth MA and American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: Drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hemangeol.1">
<a name="Hemangeol.1"></a>Hemangeol (propranolol) [prescribing information]. Parsippany, NJ: Pierre Fabre Pharmaceuticals Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hemangeol.2">
<a name="Hemangeol.2"></a>Hemangeol (propranolol) [prescribing information]. Parsippany, NJ: Pierre Fabre Pharmaceuticals, Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hemangiol.1">
<a name="Hemangiol.1"></a>Hemangiol (propranolol) [product monograph]. Brossard, Quebec, Canada: Pierre Fabre Dermo-Cosmetique Canada Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hershey.1">
<a name="Hershey.1"></a>Hershey AD, Kabbouche MA, O'Brien HL, Kacperski J. Headaches In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020: chap. 613.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-477381">
<a name="477381"></a>Hilder RJ. Propranolol and alopecia. <i>Cutis</i>. 1979;24(1):63-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/477381/pubmed" id="477381" target="_blank">477381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21788220">
<a name="21788220"></a>Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. <i>Pediatrics</i>. 2011;128(2):e259-266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/21788220/pubmed" id="21788220" target="_blank">21788220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20644039">
<a name="20644039"></a>Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. <i>Arch Dermatol</i>. 2010;146(7):775-778. doi:10.1001/archdermatol.2010.158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/20644039/pubmed" id="20644039" target="_blank">20644039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6122487">
<a name="6122487"></a>Hughes GR. Hypotensive agents, beta-blockers, and drug-induced lupus. <i>Br Med J (Clin Res Ed)</i>. 1982;284(6326):1358-1359. doi:10.1136/bmj.284.6326.1358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6122487/pubmed" id="6122487" target="_blank">6122487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InderalLA.1">
<a name="InderalLA.1"></a>Inderal LA (propranolol) [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InderalLA.2">
<a name="InderalLA.2"></a>Inderal LA (propranolol) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InderalXL.1">
<a name="InderalXL.1"></a>Inderal XL (propranolol) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InnopranXL.1">
<a name="InnopranXL.1"></a>Innopran XL (propranolol) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InnopranXL.1">
<a name="InnopranXL.1"></a>Innopran XL (propranolol) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6114116">
<a name="6114116"></a>Jacobs RL, Rake GW Jr, Fournier DC, Chilton RJ, Culver WG, Beckmann CH. Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade. <i>J Allergy Clin Immunol</i>. 1981;68(2):125-127. doi:10.1016/0091-6749(81)90170-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6114116/pubmed" id="6114116" target="_blank">6114116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1977302">
<a name="1977302"></a>Jaillon P. Relevance of intrinsic sympathomimetic activity for beta blockers. <i>Am J Cardiol</i>. 1990;66(9):21C-23C. doi:10.1016/0002-9149(90)90758-s<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1977302/pubmed" id="1977302" target="_blank">1977302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24685669">
<a name="24685669"></a>January CT, Wann LS, Alpert JS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published correction appears in <i>J Am Coll Cardiol.</i> 2014;64(21):2305-2307]. <i>J Am Coll Cardiol.</i> 2014;64(21):e1-e76. doi: 10.1016/j.jacc.2014.03.022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24685669/pubmed" id="24685669" target="_blank">24685669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30686041">
<a name="30686041"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation [published online January 28, 2019]. <i>Circulation</i>. doi: 10.1161/CIR.0000000000000665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/30686041/pubmed" id="30686041" target="_blank">30686041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29494342">
<a name="29494342"></a>Joshi K, Zacharin M. Hyperthyroidism in an infant of a mother with autoimmune hypothyroidism with positive TSH receptor antibodies. <i>J Pediatr Endocrinol Metab</i>. 2018;31(5):577-580. doi:10.1515/jpem-2017-0425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/29494342/pubmed" id="29494342" target="_blank">29494342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kannam.1">
<a name="Kannam.1"></a>Kannam JP, Gersh BJ. Beta blockers in the management of chronic coronary syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kaplan.1">
<a name="Kaplan.1"></a>Kaplan R. Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: pharmacologic therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20937444">
<a name="20937444"></a>Kavey RE, Daniels SR, Flynn JT. Management of high blood pressure in children and adolescents. <i>Cardiol Clin</i>. 2010;28(4):597-607.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/20937444/pubmed" id="20937444" target="_blank">20937444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20725536">
<a name="20725536"></a>Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. <i>J Clin Aesthet Dermatol</i>. 2010;3(1):32-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/20725536/pubmed" id="20725536" target="_blank">20725536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4127340">
<a name="4127340"></a>Kirk L, Baastrup PC, Schou M. Letter: Propranolol treatment of lithium-induced tremor. <i>Lancet</i>. 1973;2(7837):1086-1087. doi: 10.1016/s0140-6736(73)92692-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/4127340/pubmed" id="4127340" target="_blank">4127340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2">
<a name="Kliegman.2"></a>Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016: chap 562.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6376011">
<a name="6376011"></a>Kleinbaum J, Shamoon H. Effect of propranolol on delayed glucose recovery after insulin-induced hypoglycemia in normal and diabetic subjects. <i>Diabetes Care</i>. 1984;7(2):155-162. doi:10.2337/diacare.7.2.155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6376011/pubmed" id="6376011" target="_blank">6376011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12117400">
<a name="12117400"></a>Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. <i>JAMA</i>. 2002;288(3):351-357. doi:10.1001/jama.288.3.351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/12117400/pubmed" id="12117400" target="_blank">12117400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2865151">
<a name="2865151"></a>Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. <i>Eur J Clin Pharmacol</i>. 1985;28 Suppl:55-63. doi:10.1007/BF00543711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2865151/pubmed" id="2865151" target="_blank">2865151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32662682">
<a name="32662682"></a>Koh SP, Leadbitter P, Smithers F, Tan ST. β-blocker therapy for infantile hemangioma. <i>Expert Rev Clin Pharmacol</i>. 2020;13(8):899-915. doi:10.1080/17512433.2020.1788938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/32662682/pubmed" id="32662682" target="_blank">32662682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15701768">
<a name="15701768"></a>Köksal AS, Usküdar O, Köklü S, Yüksel O, Beyazit Y, Sahin B. Propranolol-exacerbated mesenteric ischemia in a patient with hyperthyroidism. <i>Ann Pharmacother</i>. 2005;39(3):559-562. doi:10.1345/aph.1E534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/15701768/pubmed" id="15701768" target="_blank">15701768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2878741">
<a name="2878741"></a>Kostis JB, Rosen RC. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties. <i>Circulation</i>. 1987;75(1):204-212. doi:10.1161/01.cir.75.1.204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2878741/pubmed" id="2878741" target="_blank">2878741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12490274">
<a name="12490274"></a>Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. <i>J Heart Lung Transplant</i>. 2002;21(12):1290-1295. doi:10.1016/s1053-2498(02)00459-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/12490274/pubmed" id="12490274" target="_blank">12490274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2577308">
<a name="2577308"></a>Kramer MS, Gorkin R, DiJohnson C. Treatment of neuroleptic-induced akathisia with propranolol: a controlled replication study. <i>Hillside J Clin Psychiatry</i>. 1989;11(2):107-119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2577308/pubmed" id="2577308" target="_blank">2577308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2906547">
<a name="2906547"></a>Kramer MS, Gorkin RA, DiJohnson C, Sheves P. Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a double-blind, placebo-controlled study. <i>Biol Psychiatry</i>. 1988;24(7):823-827.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2906547/pubmed" id="2906547" target="_blank">2906547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30584062">
<a name="30584062"></a>Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. <i>Pediatrics</i>. 2019;143(1):e20183475. doi:10.1542/peds.2018-3475<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/30584062/pubmed" id="30584062" target="_blank">30584062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-85053">
<a name="85053"></a>Lager I, Blohmé G, Smith U. Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. <i>Lancet</i>. 1979;1(8114):458-462. doi:10.1016/s0140-6736(79)90821-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/85053/pubmed" id="85053" target="_blank">85053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895792">
<a name="34895792"></a>Lam NN, Khanh PQ, An NH. The use of propranolol in adult burn patients: safety and outcome influence. <i>Burns</i>. 2022;48(4):767-773. doi:10.1016/j.burns.2021.08.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/34895792/pubmed" id="34895792" target="_blank">34895792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2439802">
<a name="2439802"></a>Lammers JW, Folgering HT, van Herwaarden CL. Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. <i>J Cardiovasc Pharmacol</i>. 1986;8 Suppl 11:S69-S73. doi:10.1097/00005344-198511001-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2439802/pubmed" id="2439802" target="_blank">2439802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24400971">
<a name="24400971"></a>Lanteri-Minet M, Valade D, Geraud G, Lucas C, Donnet A. Revised French guidelines for the diagnosis and management of migraine in adults and children. <i>J Headache Pain</i>. 2014;15(1):2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24400971/pubmed" id="24400971" target="_blank">24400971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1260604">
<a name="1260604"></a>Lapierre YD. Control of lithium tremor with propranolol. <i>Can Med Assoc J</i>. 1976;114(7):619-620, 624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1260604/pubmed" id="1260604" target="_blank">1260604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27688361">
<a name="27688361"></a>Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. <i>Pediatrics</i>. 2016;138(4):e20160353. doi:10.1542/peds.2016-0353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/27688361/pubmed" id="27688361" target="_blank">27688361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25693013">
<a name="25693013"></a>Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. <i>N Engl J Med</i>. 2015;372(8):735-746.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/25693013/pubmed" id="25693013" target="_blank">25693013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37093">
<a name="37093"></a>Lederballe Pedersen O, Mikkelsen E, Lanng Nielsen J, Christensen NJ. Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. <i>Eur J Clin Pharmacol</i>. 1979;15(3):215-217. doi:10.1007/BF00563108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/37093/pubmed" id="37093" target="_blank">37093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23154161">
<a name="23154161"></a>Léger J, Carel JC. Hyperthyroidism in childhood: causes, when and how to treat. <i>J Clin Res Pediatr Endocrinol</i>. 2013;(5 Suppl 1):50-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23154161/pubmed" id="23154161" target="_blank">23154161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24893135">
<a name="24893135"></a>Lenders JW, Duh QY, Eisenhofer G, et al; Endocrine Society. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab.</i> 2014;99(6):1915-1942. doi: 10.1210/jc.2014-1498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24893135/pubmed" id="24893135" target="_blank">24893135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22267844">
<a name="22267844"></a>Levine GN, Steinke EE, Bakaeen FG, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Quality of Care and Outcomes Research. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2012;125(8):1058-1072. doi:10.1161/CIR.0b013e3182447787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/22267844/pubmed" id="22267844" target="_blank">22267844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15623677">
<a name="15623677"></a>Lewis D, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. <i>Neurology</i>. 2004;63(12):2215-2224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/15623677/pubmed" id="15623677" target="_blank">15623677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6695818">
<a name="6695818"></a>Lewis GP, Holtzman JL. Interaction of flecainide with digoxin and propranolol. <i>Am J Cardiol</i>. 1984;53(5):52B-57B. doi:10.1016/0002-9149(84)90502-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6695818/pubmed" id="6695818" target="_blank">6695818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30076469">
<a name="30076469"></a>Li BUK. Managing cyclic vomiting syndrome in children: beyond the guidelines. <i>Eur J Pediatr</i>. 2018;177(10):1435-1442. doi:10.1007/s00431-018-3218-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/30076469/pubmed" id="30076469" target="_blank">30076469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18728540">
<a name="18728540"></a>Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. <i>J Pediatr Gastroenterol Nutr</i>. 2008;47(3):379-393. doi:10.1097/MPG.0b013e318173ed39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/18728540/pubmed" id="18728540" target="_blank">18728540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15106196">
<a name="15106196"></a>Linde K, Rossnagel K. Propranolol for migraine prophylaxis. <i>Cochrane Database Syst Rev</i>. 2004;(2):CD003225. doi: 10.1002/14651858.CD003225.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/15106196/pubmed" id="15106196" target="_blank">15106196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16049209">
<a name="16049209"></a>Lindenauer PK, Pekow P, Wang K, et al, "Perioperative Beta-Blocker Therapy and Mortality After Major Noncardiac Surgery,” <i>N Engl J Med</i>, 2005, 353(4):349-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/16049209/pubmed" id="16049209" target="_blank">16049209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27390282">
<a name="27390282"></a>Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. <i>Eur Respir J</i>. 2016;48(3):880-888. doi:10.1183/13993003.01847-2015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/27390282/pubmed" id="27390282" target="_blank">27390282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28182127">
<a name="28182127"></a>Liu X, Lou X, Cheng X, Meng Y. Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders. <i>Drug Des Devel Ther</i>. 2017;11:305-312. doi:10.2147/DDDT.S124497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/28182127/pubmed" id="28182127" target="_blank">28182127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6872291">
<a name="6872291"></a>Livingstone I, Craswell PW, Bevan EB, et al, "Propranolol in Pregnancy Three Year Prospective Study," <i>Clin Exp Hypertens B</i>, 1983, 2(2):341-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6872291/pubmed" id="6872291" target="_blank">6872291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15288162">
<a name="15288162"></a>López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. <i>Eur Heart J</i>. 2004;25(15):1341-1362. doi:10.1016/j.ehj.2004.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/15288162/pubmed" id="15288162" target="_blank">15288162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4426144">
<a name="4426144"></a>Lowenthal DT, Briggs WA, Gibson TP, Nelson H, Cirksena WJ. Pharmacokinetics of oral propranolol in chronic renal disease. <i>Clin Pharmacol Ther</i>. 1974;16(5, pt 1):761-769. doi:10.1002/cpt1974165part1761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/4426144/pubmed" id="4426144" target="_blank">4426144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36816438">
<a name="36816438"></a>Lozar Krivec J, Lah N, Glušič M, Velikonja O, Paro-Panjan D. Treatment of symptomatic focal hepatic hemangioma with propranolol in neonates: is it efficient? <i>Pediatr Gastroenterol Hepatol Nutr</i>. 2023;26(1):70-77. doi:10.5223/pghn.2023.26.1.70<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/36816438/pubmed" id="36816438" target="_blank">36816438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27899939">
<a name="27899939"></a>Lu HT, Kam J, Nordin RB, et al. Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. <i>J Geriatr Cardiol</i>. 2016;13(9):749-759. doi:10.11909/j.issn.1671-5411.2016.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/27899939/pubmed" id="27899939" target="_blank">27899939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4839065">
<a name="4839065"></a>Ludvigsson J. Propranolol used in prophylaxis of migraine in children. <i>Acta Neurol Scand</i>. 1974;50(1):109-115. doi:10.1111/j.1600-0404.1974.tb01350.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/4839065/pubmed" id="4839065" target="_blank">4839065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9391691">
<a name="9391691"></a>Luedtke S, Kuhn R, and McCaffrey F, “Pharmacologic Management of Supraventricular Tachycardias in Children. Part 2: Atrial flutter, Atrial Fibrillation, and Junctional and Atrial Ectopic Tachycardia,” <i>Ann Pharmacother</i>, 1997, 31(11):1347-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/9391691/pubmed" id="9391691" target="_blank">9391691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14998624">
<a name="14998624"></a>Lupoglazoff JM, Denjoy I, Villain E, et al. Long QT syndrome in neonates: conduction disorders associated with HERG mutations and sinus bradycardia with KCNQ1 mutations. <i>J Am Coll Cardiol</i>. 2004;43(5):826-830. doi:10.1016/j.jacc.2003.09.049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/14998624/pubmed" id="14998624" target="_blank">14998624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-526710">
<a name="526710"></a>Maclagan J, Ney UM. Investigation of the mechanism of propranolol-induced bronchoconstriction. <i>Br J Pharmacol</i>. 1979;66(3):409-418. doi:10.1111/j.1476-5381.1979.tb10846.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/526710/pubmed" id="526710" target="_blank">526710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline No. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25033579">
<a name="25033579"></a>Mandić D, Nezić L, Skrbić R. Severe hyperkalemia induced by propranolol. <i>Med Pregl</i>. 2014;67(5-6):181-184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/25033579/pubmed" id="25033579" target="_blank">25033579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manolis.1">
<a name="Manolis.1"></a>Manolis AS. Premature ventricular complexes: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6109">
<a name="6109"></a>Marshall AJ, Roberts CJ, Barritt DW. Raynaud's phenomenon as side effect of beta-blockers in hypertension. <i>Br Med J</i>. 1976;1(6024):1498-1499. doi:10.1136/bmj.1.6024.1498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6109/pubmed" id="6109" target="_blank">6109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9562933">
<a name="9562933"></a>Mayer S, Hillis LD. Prinzmetal's variant angina. <i>Clin Cardiol</i>. 1998;21(4):243-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/9562933/pubmed" id="9562933" target="_blank">9562933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969642">
<a name="1969642"></a>McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. <i>Pharmacol Ther</i>. 1990;46(2):163-197. doi:10.1016/0163-7258(90)90092-g<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1969642/pubmed" id="1969642" target="_blank">1969642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2861072">
<a name="2861072"></a>Mills GA, Horn JR. Beta-blockers and glucose control. <i>Drug Intell Clin Pharm</i>. 1985;19(4):246-251. doi:10.1177/106002808501900401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2861072/pubmed" id="2861072" target="_blank">2861072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32167428">
<a name="32167428"></a>Modarresi M, Amro A, Amro M, et al. Management of cardiogenic shock due to thyrotoxicosis: a systematic literature review. <i>Curr Cardiol Rev</i>. 2020;16(4):326-332. doi:10.2174/1573403X16666200313103657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/32167428/pubmed" id="32167428" target="_blank">32167428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19826272">
<a name="19826272"></a>Mohammadi AA, Bakhshaeekia A, Alibeigi P, et al. Efficacy of propranolol in wound healing for hospitalized burn patients. <i>J Burn Care Res</i>. 2009;30(6):1013-1017. doi:10.1097/BCR.0b013e3181b48600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/19826272/pubmed" id="19826272" target="_blank">19826272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29500811">
<a name="29500811"></a>Moon J, Kim DY, Lee WJ, et al. Efficacy of propranolol, bisoprolol, and pyridostigmine for postural tachycardia syndrome: a randomized clinical trial. <i>Neurotherapeutics</i>. 2018;15(3):785-795. doi:10.1007/s13311-018-0612-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/29500811/pubmed" id="29500811" target="_blank">29500811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24202435">
<a name="24202435"></a>Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. <i>Chest</i>. 2014;145(4):779-786. doi:10.1378/chest.13-1235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24202435/pubmed" id="24202435" target="_blank">24202435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2636593">
<a name="2636593"></a>Mukul VG. Propranolol induced Steven-Johnson syndrome. <i>J Assoc Physicians India</i>. 1989;37(12):797-798.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2636593/pubmed" id="2636593" target="_blank">2636593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10942741">
<a name="10942741"></a>Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. <i>Circulation</i>. 2000;102(7):742-747. doi: 10.1161/01.cir.102.7.742.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/10942741/pubmed" id="10942741" target="_blank">10942741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nafday.1">
<a name="Nafday.1"></a>Nafday SM, Woda CB, Saland, JM, et al. Renal disease. In: Boardman J, Groves A, Ramasethu J, eds. <i>Avery &amp; MacDonald's Neonatology - Pathophysiology and Management of the Newborn</i>. 8th ed. Lippincott Williams &amp; Wilkins; 2021: chap. 38.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, “The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,” <i>Pediatrics</i>, 2004, 114(2 Suppl):555-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Clinical Practice Guidelines, 2011. Available at <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-436208">
<a name="436208"></a>Nattel S, Rangno RE, Van Loon G. Mechanism of propranolol withdrawal phenomena. <i>Circulation</i>. 1979;59(6):1158-1164. doi:10.1161/01.cir.59.6.1158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/436208/pubmed" id="436208" target="_blank">436208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17127140">
<a name="17127140"></a>Nayak B, Burman K. Thyrotoxicosis and thyroid storm. <i>Endocrinol Metab Clin North Am</i>. 2006;35(4):663-686, vii. doi:10.1016/j.ecl.2006.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/17127140/pubmed" id="17127140" target="_blank">17127140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation. </i>2010;122(18 Suppl 3):s729-s767. doi:10.1161/CIRCULATIONAHA.110.970988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24155101">
<a name="24155101"></a>Nicolai MP, Liem SS, Both S, et al. A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. <i>Neth Heart J</i>. 2014;22(1):11-19. doi:10.1007/s12471-013-0482-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24155101/pubmed" id="24155101" target="_blank">24155101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29766868">
<a name="29766868"></a>Nikolaidou T, Ghosh JM, Clark AL. Outcomes related to first-degree atrioventricular block and therapeutic implications in patients with heart failure. <i>JACC Clin Electrophysiol</i>. 2016;2(2):181-192. doi:10.1016/j.jacep.2016.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/29766868/pubmed" id="29766868" target="_blank">29766868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481]. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6519163">
<a name="6519163"></a>O'Hare MF, Kinney CD, Murnaghan GA, et al, "Pharmacokinetics of Propranolol During Pregnancy," <i>Eur J Clin Pharmacol</i>, 1984, 27(5):583-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6519163/pubmed" id="6519163" target="_blank">6519163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3822681">
<a name="3822681"></a>Olness K, MacDonald JT, Uden DL. Comparison of self-hypnosis and propranolol in the treatment of juvenile classic migraine. <i>Pediatrics</i>. 1987;79(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/3822681/pubmed" id="3822681" target="_blank">3822681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530749">
<a name="22530749"></a>Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. <i>Pacing Clin Electrophysiol</i>. 2012;35(7):804-810. doi:10.1111/j.1540-8159.2012.03410.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/22530749/pubmed" id="22530749" target="_blank">22530749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26409259">
<a name="26409259"></a>Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/26409259/pubmed" id="26409259" target="_blank">26409259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.2">
<a name="Park.2"></a>Park MK, Salamat M. Appendix E: Drugs used in pediatric cardiology. In: <i>Park's Pediatric Cardiology for Practitioners</i>. 7th ed. Elsevier Health Sciences; 2021: 1296.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3987222">
<a name="3987222"></a>Parker WA. Propranolol-induced depression and psychosis. <i>Clin Pharm</i>. 1985;4(2):214-218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/3987222/pubmed" id="3987222" target="_blank">3987222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6344309">
<a name="6344309"></a>Patakas D, Argiropoulou V, Louridas G, Tsara V. Beta-blockers in bronchial asthma: effect of propranolol and pindolol on large and small airways. <i>Thorax</i>. 1983;38(2):108-112. doi:10.1136/thx.38.2.108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6344309/pubmed" id="6344309" target="_blank">6344309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2140288">
<a name="2140288"></a>Patten SB. Propranolol and depression: evidence from the antihypertensive trials. <i>Can J Psychiatry</i>. 1990;35(3):257-259. doi:10.1177/070674379003500312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2140288/pubmed" id="2140288" target="_blank">2140288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-758396">
<a name="758396"></a>Pickoff AS, Zies L, Ferrer PL, et al, “High-dose Propranolol Therapy in the Management of Supraventricular Tachycardia,” <i>J Pediatr</i>, 1979, 94(1):144-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/758396/pubmed" id="758396" target="_blank">758396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6376017">
<a name="6376017"></a>Popp DA, Tse TF, Shah SD, Clutter WE, Cryer PE. Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus. <i>Diabetes Care</i>. 1984;7(3):243-247. doi:10.2337/diacare.7.3.243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6376017/pubmed" id="6376017" target="_blank">6376017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1674104">
<a name="1674104"></a>Poynard T, Calès P, Pasta L, et al; Franco-Italian Multicenter Study Group. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. <i>N Engl J Med</i>. 1991;324(22):1532-1538.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1674104/pubmed" id="1674104" target="_blank">1674104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16497273">
<a name="16497273"></a>Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. <i>Biol Psychiatry</i>. 2006;59(11):1071-1077.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/16497273/pubmed" id="16497273" target="_blank">16497273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20159899">
<a name="20159899"></a>Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. <i>CMAJ</i>. 2010;182(7):E269-E276. doi: 10.1503/cmaj.081657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/20159899/pubmed" id="20159899" target="_blank">20159899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22683887">
<a name="22683887"></a>Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. <i>Can J Neurol Sci</i>. 2012;39(2)(suppl 2):S1-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/22683887/pubmed" id="22683887" target="_blank">22683887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897302">
<a name="2897302"></a>Proclemer A, Gradnik R, Savonitto S, Feruglio GA. Electrophysiological effects of bisoprolol. <i>Eur Heart J</i>. 1987;8 Suppl M:81-85. doi:10.1093/eurheartj/8.suppl_m.81<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2897302/pubmed" id="2897302" target="_blank">2897302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APP.1">
<a name="APP.1"></a>Propranolol hydrochloride injection [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Propranolol hydrochloride injection [product monograph]. Boucherville, QC, Canada: Sandoz Canada Inc; June 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pharmaceutical.1">
<a name="Pharmaceutical.1"></a>Propranolol hydrochloride oral solution [prescribing information]. Greenville, SC: Pharmaceutical Associates Inc; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Major.1">
<a name="Major.1"></a>Propranolol hydrochloride tablets [prescribing information]. Indianapolis, IN: Major Pharmaceuticals; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2450898">
<a name="2450898"></a>Prystowsky EN. The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction. <i>J Clin Pharmacol</i>. 1988;28(1):6-21. doi:10.1002/j.1552-4604.1988.tb03095.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2450898/pubmed" id="2450898" target="_blank">2450898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1968518">
<a name="1968518"></a>Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. <i>JAMA</i>. 1990;263(12):1653-1657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1968518/pubmed" id="1968518" target="_blank">1968518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19687359">
<a name="19687359"></a>Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. <i>Circulation</i>. 2009;120(9):725-734. doi:10.1161/CIRCULATIONAHA.108.846501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/19687359/pubmed" id="19687359" target="_blank">19687359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32145864">
<a name="32145864"></a>Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. <i>Can J Cardiol.</i> 2020;36(3):357-372. doi:10.1016/j.cjca.2019.12.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/32145864/pubmed" id="32145864" target="_blank">32145864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26995368">
<a name="26995368"></a>Ranchord AM, Spertus JA, Buchanan DM, Gosch KL, Chan PS. Initiation of β-blocker therapy and depression after acute myocardial infarction. <i>Am Heart J</i>. 2016;174:37-42. doi:10.1016/j.ahj.2015.11.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/26995368/pubmed" id="26995368" target="_blank">26995368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6125187">
<a name="6125187"></a>Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. <i>Br J Clin Pharmacol</i>. 1982;13(Suppl 2):345S-351S. doi:10.1111/j.1365-2125.1982.tb01939.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6125187/pubmed" id="6125187" target="_blank">6125187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1576764">
<a name="1576764"></a>Rasoulpour M and Marinelli KA, “Systemic Hypertension,” <i>Clin Perinatol</i>, 1992, 19(1):121-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1576764/pubmed" id="1576764" target="_blank">1576764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32771652">
<a name="32771652"></a>Relan J, Gujral JS, Reddy SS, Parakh N, Singh S, Ramakrishnan S. Long QT syndrome with AV Wenckebaching &amp; bundle branch block in a neonate. <i>Indian Pacing Electrophysiol J</i>. 2020;20(6):286-289. doi:10.1016/j.ipej.2020.07.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/32771652/pubmed" id="32771652" target="_blank">32771652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35979094">
<a name="35979094"></a>Ren N, Jin CS, Zhao XQ, et al. Preterm neonate with a large congenital hemangioma on maxillofacial site causing thrombocytopenia and heart failure: a case report. <i>World J Clin Cases</i>. 2022;10(17):5756-5763. doi:10.12998/wjcc.v10.i17.5756<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/35979094/pubmed" id="35979094" target="_blank">35979094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi: 10.1016/j.jash.2015.03.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.1">
<a name="Ross.1"></a>Ross DS. Thyroid storm. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521067">
<a name="27521067"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421. doi 10.1089/thy.2016.0229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/27521067/pubmed" id="27521067" target="_blank">27521067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23582468">
<a name="23582468"></a>Rousseau AF, Losser MR, Ichai C, Berger MM. ESPEN endorsed recommendations: nutritional therapy in major burns. <i>Clin Nutr</i>. 2013;32(4):497-502. doi:10.1016/j.clnu.2013.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23582468/pubmed" id="23582468" target="_blank">23582468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3608376">
<a name="3608376"></a>Rubin PC, Butters L, McCabe R, et al, "The Influence of Pregnancy on Drug Action: Concentration-Effect Modelling With Propranolol," <i>Clin Sci (Lond)</i>, 1987, 73(1):47-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/3608376/pubmed" id="3608376" target="_blank">3608376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22962431">
<a name="22962431"></a>Sanatani S, Potts JE, Reed JH, et al. The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. <i>Circ Arrhythm Electrophysiol</i>. 2012;5(5):984-991.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/22962431/pubmed" id="22962431" target="_blank">22962431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanyal.1">
<a name="Sanyal.1"></a>Sanyal AJ, Garcia-Pagán JC. Primary prevention of bleeding from esophageal varices in patients with cirrhosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 29, 2019b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanyal.2">
<a name="Sanyal.2"></a>Sanyal AJ, Bajaj AS. Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2019a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23024438">
<a name="23024438"></a>Scheer FA, Morris CJ, Garcia JI, et al. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. <i>Sleep</i>. 2012;35(10):1395-1402. doi:10.5665/sleep.2122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/23024438/pubmed" id="23024438" target="_blank">23024438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14676229">
<a name="14676229"></a>Schulze-Bahr E, Fenge H, Etzrodt D, et al. Long QT syndrome and life threatening arrhythmia in a newborn: molecular diagnosis and treatment response. <i>Heart</i>. 2004;90(1):13-16. doi:10.1136/heart.90.1.13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/14676229/pubmed" id="14676229" target="_blank">14676229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.2022">
<a name="Schwedt.2022"></a>Schwedt TJ, Garza I. Preventive treatment of episodic migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28622464">
<a name="28622464"></a>Semet M, Paci M, Saïas-Magnan J, et al. The impact of drugs on male fertility: a review. <i>Andrology</i>. 2017;5(4):640-663. doi:10.1111/andr.12366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/28622464/pubmed" id="28622464" target="_blank">28622464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-668066">
<a name="668066"></a>Shand DG, Wood AJ. Propranolol withdrawal syndrome - why? <i>Circulation</i>. 1978;58(2):202-203. doi:10.1161/01.cir.58.2.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/668066/pubmed" id="668066" target="_blank">668066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25980576">
<a name="25980576"></a>Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. <i>Heart Rhythm</i>. 2015;12(6):e41-e63. doi:10.1016/j.hrthm.2015.03.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/25980576/pubmed" id="25980576" target="_blank">25980576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14585251">
<a name="14585251"></a>Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. <i>Eur Heart J</i>. 2003;24(21):1928-1932. doi:10.1016/j.ehj.2003.08.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/14585251/pubmed" id="14585251" target="_blank">14585251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3718646">
<a name="3718646"></a>Skalina ME, Kliegman RM, Fanaroff AA. Epidemiology and management of severe symptomatic neonatal hypertension. <i>Am J Perinatol</i>. 1986;3(3):235-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/3718646/pubmed" id="3718646" target="_blank">3718646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smith.1">
<a name="Smith.1"></a>Smith JR and Wassner AJ. Thyrotoxicosis. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020: chap. 584.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11298090">
<a name="11298090"></a>Smith C, Thomsett M, Choong C, Rodda C, McIntyre HD, Cotterill AM. Congenital thyrotoxicosis in premature infants. <i>Clin Endocrinol (Oxf)</i>. 2001;54(3):371-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/11298090/pubmed" id="11298090" target="_blank">11298090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6845404">
<a name="6845404"></a>Smith MT, Livingstone I, Hooper WD, Eadie MJ, Triggs EJ. Propranolol, propranolol glucuronide, and naphthoxylactic acid in breast milk and plasma. <i>Ther Drug Monit.</i> 1983;5(1):87-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/6845404/pubmed" id="6845404" target="_blank">6845404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052934">
<a name="22052934"></a>Smith SC Jr, Benjamin EJ, Bonow RO, et al, “AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,” <i>Circulation</i>, 2011, 124(22):2458-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/22052934/pubmed" id="22052934" target="_blank">22052934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12454689">
<a name="12454689"></a>Sommer F, Schwarzer U, Wassmer G, et al. Epidemiology of Peyronie's disease. <i>Int J Impot Res</i>. 2002;14(5):379-383. doi:10.1038/sj.ijir.3900863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/12454689/pubmed" id="12454689" target="_blank">12454689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25183382">
<a name="25183382"></a>Soussan C, Gouraud A, Portolan G, et al. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. <i>Eur J Clin Pharmacol</i>. 2014;70(11):1361-1366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/25183382/pubmed" id="25183382" target="_blank">25183382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.1">
<a name="Stein.1"></a>Stein MB. Pharmacotherapy for social anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 5, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign Against Headache. <i>J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-947574">
<a name="947574"></a>Strauss HC, Gilbert M, Svenson RH, Miller HC, Wallace AG. Electrophysiologic effects of propranolol on sinus node function in patients with sinus node dysfunction. <i>Circulation</i>. 1976;54(3):452-459. doi:10.1161/01.cir.54.3.452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/947574/pubmed" id="947574" target="_blank">947574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.2021">
<a name="Stroup.2021"></a>Stroup TS, Marder S. Schizophrenia in adults: maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sunku.2009">
<a name="Sunku.2009"></a>Sunku B. Cyclic vomiting syndrome: a disorder of all ages. <i>J Gastroenterol Hepatol</i>. 2009;5(7):507-515.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34331033">
<a name="34331033"></a>Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. <i>Nat Rev Cardiol</i>. 2022;19(1):59-74. doi:10.1038/s41569-021-00593-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/34331033/pubmed" id="34331033" target="_blank">34331033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25887380">
<a name="25887380"></a>Tripathi D, Stanley AJ, Hayes PC, et al; Clinical Services and Standards Committee of the British Society of Gastroenterology. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. <i>Gut</i>. 2015;64(11):1680-1704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/25887380/pubmed" id="25887380" target="_blank">25887380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28559400">
<a name="28559400"></a>Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H. Risk of cardiovascular events in patients with diabetes mellitus on β-blockers. <i>Hypertension</i>. 2017;70(1):103-110. doi:10.1161/HYPERTENSIONAHA.117.09259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/28559400/pubmed" id="28559400" target="_blank">28559400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073535">
<a name="32073535"></a>Viigimaa M, Vlachopoulos C, Doumas M, et al; European Society of Hypertension Working Group on Sexual Dysfunction. Update of the position paper on arterial hypertension and erectile dysfunction. <i>J Hypertens</i>. 2020;38(7):1220-1234. doi:10.1097/HJH.0000000000002382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/32073535/pubmed" id="32073535" target="_blank">32073535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vue.1">
<a name="Vue.1"></a>Vue MH, Setter SM. Drug-induced glucose alterations part 1: drug-induced hypoglycemia. <i>Diabetes Spectrum,</i> 2011;24(3):171-177.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hyperten (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2865153">
<a name="2865153"></a>Westerlund A. Central nervous system side-effects with hydrophilic and lipophilic beta-blockers. <i>Eur J Clin Pharmacol</i>. 1985;28 Suppl:73-76. doi:10.1007/BF00543714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/2865153/pubmed" id="2865153" target="_blank">2865153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Hypertension</i>. 2018;71(6):e140-e144]. <i>Hypertension</i>. 2018;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5572397">
<a name="5572397"></a>Wilkinson R, Luetscher JA, Goldman RH. Serum enzymes and propranolol. <i>Br Med J</i>. 1971;2(5756):276-277. doi:10.1136/bmj.2.5756.276-c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/5572397/pubmed" id="5572397" target="_blank">5572397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1603141">
<a name="1603141"></a>Woeber KA. Thyrotoxicosis and the heart. <i>N Engl J Med</i>. 1992;327(2):94-98. doi:10.1056/NEJM199207093270206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1603141/pubmed" id="1603141" target="_blank">1603141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7470370">
<a name="7470370"></a>Wood AJ, Vestal RE, Spannuth CL, Stone WJ, Wilkinson GR, Shand DG. Propranolol disposition in renal failure. <i>Br J Clin Pharmacol</i>. 1980;10(6):561-566. doi:10.1111/j.1365-2125.1980.tb00511.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/7470370/pubmed" id="7470370" target="_blank">7470370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at https://apps.who.int/iris/handle/10665/62435.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1354194">
<a name="1354194"></a>Wynn RL, “Dental Nonsteroidal Anti-inflammatory Drugs and Prostaglandin-Based Drug Interactions, Part Two,” <i>Gen Dent</i>, 1992, 40(2):104, 106, 108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/1354194/pubmed" id="1354194" target="_blank">1354194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7911769">
<a name="7911769"></a>Wynn RL, “Epinephrine Interactions With Beta-Blockers,” <i>Gen Dent</i>, 1994, 42(1):16, 18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/7911769/pubmed" id="7911769" target="_blank">7911769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Young.1">
<a name="Young.1"></a>Young WF Jr, Kebebew E. Treatment of pheochromocytoma in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15234417">
<a name="15234417"></a>Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. <i>J Am Coll Cardiol</i>. 2004;44(1):105-108. doi:10.1016/j.jacc.2004.03.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/15234417/pubmed" id="15234417" target="_blank">15234417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22013182">
<a name="22013182"></a>Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2011;77(19):1752-1755. doi: 10.1212/WNL.0b013e318236f0fd.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/22013182/pubmed" id="22013182" target="_blank">22013182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15972843">
<a name="15972843"></a>Zesiewicz TA, Elble R, Louis ED, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2005;64(12):2008-2020. doi: 10.1212/01.WNL.0000163769.28552.CD.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/15972843/pubmed" id="15972843" target="_blank">15972843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30334996">
<a name="30334996"></a>Zhu Z, Cai P, Zhu J, et al. Neonatal giant hepatic hemangioma: a case report. <i>Medicine (Baltimore)</i>. 2018;97(42):e12863. doi:10.1097/MD.0000000000012863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propranolol-drug-information/abstract-text/30334996/pubmed" id="30334996" target="_blank">30334996</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9829 Version 684.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
